picture
RJR-logo

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

icon

Bibliography Options Menu

icon
QUERY RUN:
17 Nov 2026 at 01:36
HITS:
52300
PAGE OPTIONS:
Hide Abstracts   |   Hide Additional Links
NOTE:
Long bibliographies are displayed in blocks of 100 citations at a time. At the end of each block there is an option to load the next block.

Bibliography on: Alzheimer Disease — Current Literature

RJR-3x

Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About:  RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE

RJR: Recommended Bibliography 17 Nov 2026 at 01:36 Created: 

Alzheimer Disease — Current Literature

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.

Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion

Citations The Papers (from PubMed®)

-->

RevDate: 2026-11-15

Mecca AP (2026)

Considering evoke and evoke+ outcomes for future Alzheimer's disease drug development.

RevDate: 2026-11-15

Zhen Y, Zhang K, Li S, et al (2026)

The disrupted navigational compass: pathophysiological mechanisms and clinical interventions for spatial navigation deficits.

Neuroscience and biobehavioral reviews pii:S0149-7634(26)00551-8 [Epub ahead of print].

Spatial navigation is a higher-order integrative cognitive ability that supports environmental orientation, goal-directed route selection, and adaptive locomotion by integrating spatial memory, multisensory cues, attention, and executive control. Neural systems supporting navigation are also vulnerable to aging and neurodegenerative disease, making navigation a useful domain for linking basic mechanisms with clinically measurable functional impairment. This review summarizes spatial-navigation mechanisms across multiple levels. At the cognitive level, navigation depends on interacting processes including spatial representation, path integration, reference-frame transformation, landmark use, and route planning. At the network level, hippocampal-entorhinal, retrosplenial-parietal, scene-selective, and prefrontal systems contribute complementary functions. At the cellular level, place-, grid-, head-direction-, speed-, and boundary-related representations encode position, heading, self-motion, environmental geometry, and prospective behavior. Clinical and neuroimaging studies indicate that navigation impairment is associated with structural and functional abnormalities, with the strongest diagnostic evidence currently arising from Alzheimer's disease and its prodromal stages. VR-based behavioral assessment and electrophysiological approaches provide complementary means of characterizing navigation phenotypes: VR enables controlled, repeatable, process-sensitive tasks, whereas intracranial and scalp recordings provide neural information at different spatial and physiological scales. No pharmacological agent has been developed or licensed specifically for navigation impairment; current navigation-focused interventions therefore rely mainly on behavioral and VR-based rehabilitation, compensatory strategies, and emerging neuromodulation approaches. Future studies should integrate process-specific behavioral and physiological markers with biomarker-defined clinical cohorts, and use large, randomized, longitudinal studies to establish diagnostic validity, real-world transfer, and mechanism-informed intervention effects.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Sharma A, Singh G, Mannan A, et al (2026)

Toll-Like Receptor-Driven Neuroinflammation in Neurological Disorders: Signaling Crosstalk and Therapeutic Opportunities.

Journal of neuroscience research, 104(11):.

Toll-like receptors (TLRs) serve as pivotal mediators bridging innate immunity and neuroinflammation, orchestrating pathological cascades that drive neurological disorders. Beyond their sentinel role in pathogen recognition, aberrant TLR activation triggers intricate and destructive signaling networks, including activation of NF-κB, MAPK, JAK/STAT, and PI3K/AKT, alongside IRFs and type I interferon responses that converge on chronic neuroinflammation and subsequent neuronal damage. This review dissects TLRs' multilayered contribution to neuropathology, emphasizing their regulation of secondary inflammatory mechanisms, including NLRP3 inflammasome priming and activation, mTOR-driven metabolic dysregulation, SOCS-mediated feedback inhibition, inflammasome activation, and pyroptotic cell death. Critically, these signaling pathways create a pathological intersection with oxidative stress and mitochondrial dysfunction, amplifying a self-perpetuating cycle of neuronal injury that underlies conditions like Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and Amyotrophic lateral sclerosis (ALS), Stroke, Multiple sclerosis (MS), Epilepsy and Traumatic brain injury (TBI). Against this neuropathological landscape, this review systematically evaluates emerging therapeutic strategies targeting TLR-mediated neuroinflammation, encompassing small molecule TLR antagonists, intracellular adaptor protein inhibitors targeting myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF), biologic therapies including monoclonal antibodies and fusion proteins, natural phytochemicals and nutraceuticals, Clustered regularly interspaced short palindromic repeats (CRISPR)-based genomic interventions, and cell-based immunomodulatory therapies, collectively representing a mechanistically diverse arsenal aimed at recalibrating the dysregulated innate immune response to achieve durable neuroprotection across the full spectrum of TLR-mediated neurological disorders.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Cai WJ, Xie YJ, Liu XR, et al (2026)

[Research progress on early biomarkers of Alzheimer's disease].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 60(11):1854-1861.

As the global population continues to age, Alzheimer's disease (AD) has become a serious public health issue. Compared to traditional diagnostic methods, blood biomarkers offer new avenues for early AD screening due to their advantages, such as low invasiveness and high throughput. In 2024, the National Institute on Aging-Alzheimer's Association (NIA-AA) updated its ATN biomarker research framework, in which A, T, and N denote β-amyloid, tau, and neurodegeneration (hereafter the ATN framework), formally establishing the diagnostic status of blood biomarkers and proposing Core 1 and Core 2 biomarkers for disease diagnosis and pathological staging; and atypical biomarkers, such as those related to neurodegeneration, inflammation, vascular damage, and comorbid proteins, to reflect mixed pathological states. Although these markers show substantial potential for early AD screening, their clinical translation is still limited by insufficient standardisation across assay platforms and by assay interference. This review summarises recent advances in early AD biomarkers and outlines the challenges and prospects for their translation.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Salari A, Taheri M, Khalili M, et al (2026)

Simvastatin Alleviation of Trimethyltin-Induced Hippocampal and Behavioral Impairments via Improvement of Antioxidants, Mitochondrial Health, and Energy Homeostasis.

Pharmacology research & perspectives, 14(6):.

Mitochondrial dysfunction and antioxidant deficiency are key contributors to the pathogenesis of Alzheimer's disease (AD). Trimethyltin (TMT) induces selective hippocampal damage associated with redox disequilibrium, neuroinflammatory responses, mitochondrial dysfunction, and impaired energy homeostasis, leading to cognitive decline. The present study evaluated whether simvastatin as a lipid-lowering and protective medicine could mitigate TMT-induced behavioral abnormalities by improving hippocampal antioxidant status, mitochondrial integrity, and energy homeostasis. Rats were assigned to control, control + simvastatin (30 mg/kg), TMT, TMT + simvastatin (10 mg/kg), and TMT + simvastatin (30 mg/kg) groups. TMT was injected IP (once, 8 mg/kg) to instigate neurotoxicity. Following three weeks of treatment, locomotor activity and conditioned learning and memory deficits were analyzed using open-field and passive avoidance tests, respectively. Besides, hippocampal levels or activity of nitrite, glutathione (GSH), glutathione peroxidase (GPx), myeloperoxidase (MPO), and β-site APP-cleaving enzyme 1 (BACE1), mitochondrial membrane potential (MMP), and AMP-activated protein kinase (AMPK) were measured. Simvastatin treatment (30 mg/kg) was associated with higher latency in the passive avoidance test and longer rearing in the open field test in TMT-intoxicated rats. Additionally, simvastatin improved hippocampal GSH, GPx, MMP, and AMPK and mitigated MPO activity relative to the TMT group but did not significantly affect nitrite or BACE-1 activity. Collectively, simvastatin mitigated TMT-induced neurobehavioral impairment, partly through restoration of antioxidants and mitochondrial health in association with AMPK.

RevDate: 2026-11-16
CmpDate: 2026-11-15

Suo X, Feng Q, Lu H, et al (2026)

Protective effects of rs7315280 on hippocampal volume and cognitive decline in aging by its enhancer activity regulating TESC expression.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47(12):.

BACKGROUND: Hippocampal atrophy is a core biomarker of Alzheimer's disease (AD), yet the cognitive relevance and molecular function of its genetic determinants remain largely unknown. In this study, we aimed to bridge this critical gap by systematically identifying and functionally characterizing a key genetic determinant of hippocampal volume and its role in AD.

METHODS: We performed a cross-cohort Genome-wide association studies (GWAS) meta-analysis using data from UK Biobank (n = 33,731) and ENIGMA (n = 26,814). Phenotypic associations were validated in the ADNI-1 cohort (n = 756), adjusting for polygenic risk scores (PRS). Functional characterization included in silico annotation (3DSNP/ENCODE), dual-luciferase reporter assays, and brain-specific eQTL analysis.

RESULTS: We identified rs7315280 (A > G) as a lead genetic variant associated with hippocampal volume via meta-GWAS analysis (all P ≤ 1.37 × 10[-19]). In ADNI-1, G allele carriers had larger hippocampal volumes (P = 0.004), a lower AD conversion rate (3%), delayed disease onset (P = 0.015), and an odds ratio for AD of 0.663. rs7315280 localizes to hippocampal enhancer regions and binds 51 transcription factors (e.g., CTCF). The G allele enhanced transcriptional activity (P = 0.002), and rs7315280 was linked to TESC expression in the human prefrontal cortex (P = 1.30 × 10⁻[5]).

CONCLUSIONS: Our findings suggest that rs7315280 may contribute to protection against AD by acting as an enhancer regulating TESC expression, identifying a potential novel genetic locus and a candidate therapeutic target for further investigation.

RevDate: 2026-11-15

Tschui V, Pugeda T, Swierczek U, et al (2026)

CD22 loss enhances phagocytosis in myeloid cells and ameliorates Alzheimer's disease-like pathology in mice.

The EMBO journal [Epub ahead of print].

CD22, an inhibitory receptor canonically expressed in B cells, is also present in microglia of the murine central nervous system. In the human brain, CD22 was predominantly found in oligodendrocytes, but also in a subset of brain-resident myeloid cells from patients with Alzheimer's disease, while it is also expressed in peripheral monocytes and differentiated THP-1 cells. CD22 has been implicated as a negative regulator of microglial phagocytosis. Here, we demonstrate that genetic ablation of CD22 in APPPS1 transgenic mice, a widely used murine model of Alzheimer's disease-like pathology, attenuates amyloid-β pathology and protects parvalbumin-positive interneurons in an age-dependent manner. Mechanistically, microglia and differentiated THP-1 cells lacking CD22 exhibit enhanced activation and phagocytosis following stimulation of the pattern-recognition receptor CLEC7A, mediated by increased SYK signaling. Conversely, activation of CD22 with the agonistic antibody epratuzumab suppresses activation of differentiated THP-1 cells. Our findings identify a CLEC7A-CD22-SYK signaling axis in both human and murine myeloid cells, in which CD22 functions as an inhibitory regulator of CLEC7A-mediated cell activation.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Varshavskaya KB, Barykin EP, Korokin MV, et al (2026)

Tetrapeptide НАЕЕ Inhibits the Toxic Effect of Beta-Amyloid on NEURO2A Neuroblastoma Cells.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 529(1):244-247.

Alzheimer's disease (AD) is characterized by the accumulation of beta-amyloid (Aβ), which plays a key role in the pathogenesis of the disease. Levels of the tetrapeptide HAEE, an endogenous component of human blood, are significantly reduced in AD patients. In this study, we demonstrated that HAEE protects Neuro2a cells from the cytotoxic effects of Aβ by preventing necrosis, apoptosis, and the decline in mitochondrial potential, as well as by reducing Aβ internalization. These findings demonstrate the potential of HAEE as a therapeutic agent for the treatment of AD.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Koltunova LA, Zaripov PI, Mkhitaryan EA, et al (2026)

Increase in IgM Autoantibodies to Aβ1-42 in Plasma of Men with Alzheimer's disease.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 529(1):278-281.

The pathogenesis of Alzheimer's disease (AD) is associated with impaired metabolism of the beta‑amyloid peptide (Aβ), which acts not only as a pathogenetically significant factor but also as a potential autoantigen capable of inducing a humoral immune response. In contrast to IgG antibodies to Aβ, which have been studied quite extensively, the levels of IgM antibodies to this peptide in AD patients and healthy donors remain poorly investigated. In the present study, we performed a comparative evaluation of IgM titers to Aβ1-42 in the peripheral blood plasma of 26 AD patients and 26 healthy donors using enzyme‑linked immunosorbent assay (ELISA). The obtained data demonstrate a statistically significant elevation of IgM antibody titers to Aβ1-42 in the plasma of men with AD compared to the healthy donor group.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Shi S, W Liu (2026)

Lost balance: synergy-redundancy dysfunction in Alzheimer's disease.

BMC geriatrics, 26(1):.

Alzheimer's disease (AD) is the most common neurodegenerative disorder, yet reliable early biomarkers are still lacking, which greatly hinders timely intervention for AD. This study employed an integrated information decomposition framework to systematically investigate the dynamic evolution of brain synergy and redundancy information in different AD stages and their associations with cognitive function, aiming to explore potential novel biomarkers for AD early diagnosis. The results show that, compared with the cognitively normal (CN) group, the cognitively abnormal (CA) group exhibited a distinct pattern of enhanced synergy and reduced redundancy. This pattern difference is primarily distributed within the default mode network (DMN), and is significant even in early-stages of AD, indicating that synergy-redundancy information is a promising biomarker for AD early diagnosis. Despite the inclusion of cognitively impaired individuals, functional decoding analyses still revealed that synergy mainly supported higher-level cognitive and social functions, whereas redundancy was more related to sensorimotor and basic cognitive functions. Additionally, compared to the CN group, the CA group exhibited stronger positive synergy correlations in brain regions related to working memory and cognitive control, possibly reflecting compensatory mechanisms, while negative synergy correlations were observed in pain-processing regions, potentially linked to impaired sensory perception. Stronger positive redundancy correlations in motor-related regions but negative correlations in reward-related regions, may suggest AD-related selective reorganization of information processing. Finally, a machine learning model constructed based on synergy-redundancy information demonstrated superior performance in AD stage classification, providing new insights for AD early diagnosis and further validating the potential of synergy-redundancy information as early biomarkers.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Jiang Y, Albornoz EA, Zheng H, et al (2026)

Inflammation-associated serum amyloid A amplifies amyloid-β-driven oxidative stress and microglial activation.

Journal of neuroinflammation, 23(1):.

Systemic inflammation is increasingly recognised as a key modifier of Alzheimer's disease (AD) progression, yet the mechanisms linking inflammatory acute-phase responses to Amyloid-β (Aβ)-driven neurotoxicity remain incompletely defined. Here, we report that amyloidogenic acute-phase peptide fragment SAA19-45 (SAA27), derived from Serum Amyloid A (SAA), modulates Aβ aggregation and amplifies downstream oxidative and inflammatory stress responses in neuronal and microglial systems.Immunofluorescence analysis of human AD brain tissue revealed plaque-associated SAA-positive cellular structures within or adjacent to Aβ-positive pathological microenvironments across all range of Braak stages. In vitro, co-incubation of SAA27 with Aβ accelerated Thioflavin T-positive aggregation kinetics and altered fibrillar organisation. In SH-SY5Y neurons, Aβ induced marked cytotoxicity and oxidative stress, and SAA27 selectively enhanced intracellular reactive oxygen species without a proportional increase in cell death. In HMC3 microglia, Aβ triggered oxidative stress and inflammatory activation, both of which were further amplified by SAA27, as reflected by increased reactive oxygen species and elevated IL-6 secretion. Similarly, SAA27 enhanced Aβ-induced IL-1β release in monocyte-derived microglia-like cells. In zebrafish larvae, Aβ and SAA27 co-injection produced a stronger ThT-positive amyloid signal and synaptic degeneration, compared with Aβ alone, supporting enhanced amyloid accumulation and synaptic disruption in vivo. Quantitative proteomics revealed Aβ-driven stress and proteostasis-related reprogramming in both neurons and microglia, with SAA27 biasing these responses toward oxidative and activation-associated pathways consistent with microglial remodelling and immune engagement. The polyphenol epigallocatechin gallate (EGCG) suppressed fibrillar aggregation in vitro and in zebrafish larvae, preserved synaptic integrity in vivo, attenuated oxidative and inflammatory responses, and differentially modulated cellular proteomic states, promoting near-restoration in neurons while inducing a distinct, less stress-associated state in microglia.Together, these findings identify SAA27 as an inflammation-associated co-factor that accelerates Aβ assembly and amplifies oxidative and innate immune stress responses. The observed partial overlap with human AD proteomic signatures further supports the disease relevance of these pathways. This work provides mechanistic insight into how systemic inflammatory states may exacerbate amyloid-driven neuroinflammation in AD and highlights inflammation-amyloid crosstalk as a pharmacologically modifiable axis.

RevDate: 2026-11-15

Qiu Z (2026)

Recombinant AAV-Based Gene Therapy for Central Nervous System Disorders: From Gene Replacement to Precision Editing and Circuit Modulation.

Human gene therapy [Epub ahead of print].

Recombinant adeno-associated virus (rAAV) vectors have moved central nervous system (CNS) gene therapy from experimental proof of concept to clinically validated treatment, yet therapeutic design remains highly dependent on disease mechanism, cellular distribution, and treatment timing. This narrative review examines recent progress in rAAV-based interventions for neurodevelopmental disorders (NDDs) and neurodegenerative disorders. For monogenic NDDs, gene replacement is most applicable to loss-of-function conditions with compatible payload size and tolerable expression, whereas dominant-negative, gain-of-function, and dosage-sensitive disorders may require allele-selective silencing or precise DNA or RNA editing. Rett syndrome illustrates both the reversibility of postnatal dysfunction and the need for tightly regulated transgene expression. Spinal muscular atrophy provides the leading translational paradigm: rAAV9-mediated SMN1 replacement demonstrates the value of early diagnosis, adequate tissue exposure, and treatment before irreversible neuronal loss. For complex neurodegenerative diseases, emerging strategies extend beyond simple gene addition. APOE-directed editing and protective-variant replacement may enable genotype-informed intervention in Alzheimer's disease, whereas Parkinson's disease programs combine restoration of dopamine synthesis, neuroprotection, and genetically encoded circuit modulation. Across these indications, major barriers include incomplete and nonselective CNS delivery, immune and dose-related toxicity, limited redosing, durable control of transgene or editor activity, off-target effects, and uncertain translation from animal models to humans. Progress over the next decade will depend on human-compatible vectors, cell-selective and regulatable expression, rigorous long-term safety assessment, biomarker-guided trials, and rational combinations that connect molecular target engagement to meaningful neurological benefit.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Abubakar M, Giri A, Goel F, et al (2026)

Corrigendum to: Diabestes, Alzheimer's Disease Risk Factors, and the Cafeteria Diet: A Comprehensive Review.

Current neuropharmacology, 24(12):1984.

We have identified that reference numbers 81 and 93 in the published version of this article [1] were inadvertently published incompletely. Details of the error and the correction are provided below: ORIGINAL [81] Hughes, E. Gut health: Efficacy of supplementation when it comes to IBS. 2020. Available from: [93] Desmet, L. Tuning feeding time to prevent the effects of chronodisruption in the gut induced by chronic jetlag. 2022. Available from: CORRECTED [81] Hughes, E. Gut health: Efficacy of supplementation when it comes to IBS. 2020. [93] Desmet L. Tuning feeding time to prevent the effects of chronodisruption in the gut induced by chronic jetlag [dissertation on the Internet]. Leuven (BE): KU Leuven; 2022. Available from: https://lirias.kuleuven.be/handle/20.500.12942/689311 The original article has been updated accordingly. This corrigendum is published to ensure transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/149266. The authors regret these errors and apologise for any inconvenience they may have caused.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Abgueguen E, Henriques A, Callizot N, et al (2026)

Sephin1 protects from glutamate stress, consistent with negative allosteric modulation of GluN2B-containing NMDA receptor.

Biochemistry and biophysics reports, 48:102879.

Glutamate excitotoxicity and GluN2B containing N-methyl-d-aspartate receptors (NMDARs) are involved in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Parkinson disease and Alzheimer disease. Recently, Sephin1, a first-in-class, multi-functional, brain-penetrant, orally administered small molecule, has been demonstrated in vitro to improve motor neurons survival following glutamate intoxication. In ALS animal models, Sephin1 was able to reduce motor neuron loss, to improve motor function and increase animal survival. To determine how Sephin1 can reduce motor neurons loss following glutamate intoxication, calcium flux was measured in primary cortical neurons and in GluN1A/GluN2B overexpressing cells following NMDA stimulation. Then, to determine the binding site on GluN1 and GluN2B subunits, binding assays were performed with three benzylideneaminoguanidine derivatives, Sephin1, guanabenz and IFB-048. Here, for the first time, we show that Sephin1 reduces calcium flux in NMDA stimulated primary cortical neurons in a dose dependent manner. Sephin1, guanabenz and IFB-048 reduce the rise of calcium flux in GluN1A/GluN2B subunits overexpressing cells stimulated with NMDA. In addition, we demonstrated that Sephin1, guanabenz and IFB-048, displace ifenprodil from the N-terminal domain (NTD) of NMDAR (GluN1/GluN2B) containing the polyamine site on GluN2B subunits. The three benzylideneaminoguanidine derivatives could possibly be Negative Allosteric Modulator (NAM) of GluN2B-containing NMDARs.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Han C, Z Guo (2026)

Neuroimaging of Anxiety in Mild Cognitive Impairment: Integrating Structural, Functional, Molecular, and Network Perspectives-A Narrative Review.

International journal of general medicine, 19:651366.

This narrative review summarizes neuroimaging evidence on the neurobiological correlates of anxiety symptoms in mild cognitive impairment (MCI) across the Alzheimer's disease continuum. A literature search was conducted in PubMed from 1 January 2015 to 30 June 2026. Structural magnetic resonance imaging studies link anxiety to atrophy in medial temporal and prefrontal-limbic regions, with white matter disruption in the cingulum bundle and uncinate fasciculus. Functional magnetic resonance imaging shows altered interactions among the default mode network, salience network, and central executive network. Molecular imaging points to limbic glucose hypometabolism, amyloid deposition, and neuroinflammation. Emerging vascular and peripheral biomarker data further implicate blood-brain barrier disruption and gut-brain axis alterations. Most of the literature is cross-sectional and relies on heterogeneous anxiety assessments. Findings are further complicated by symptom overlap with depression and other neuropsychiatric manifestations, and anxiety-specific imaging studies in MCI are relatively scarce. Direct evidence specific to anxiety in MCI remains limited; some findings discussed here are derived from studies of Alzheimer's disease dementia or general neuropsychiatric symptoms and should be interpreted accordingly. Longitudinal multimodal designs, standardized anxiety-specific instruments, and integrative models linking symptom dimensions to imaging and fluid biomarkers are needed to disentangle whether anxiety in MCI represents an early marker of neurodegeneration, a disease-course modifier, or both.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Mohammadi L, Roghani M, T Baluchnejadmojarad (2026)

Linagliptin as a Multi-Target Neuroprotective Agent in Cognitive Disorders: Molecular Mechanisms and Translational Challenges-A Narrative Review.

Drug design, development and therapy, 20:645071.

Cognitive disorders, which are characterized by progressive impairment of memory, language, and other cognitive functions, are a growing global health challenge. Currently, there are limited therapeutic options available to prevent or reverse the progression of these disorders. Linagliptin, an approved treatment for type 2 diabetes, has recently emerged as a neuroprotective agent, offering benefits beyond its glucose-lowering effects. Preclinical studies have demonstrated that linagliptin improves cognitive performance and protects neuronal integrity in various experimental models, including Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia, diabetic cognitive dysfunction, demyelination, and toxicant-induced cognitive impairment. The neuroprotective actions of linagliptin are mediated through multiple mechanisms, including the attenuation of endoplasmic reticulum (ER) stress, mitochondrial dysfunction, neuroinflammation, and oxidative stress, as well as the inhibition of apoptotic pathways, preservation of blood-brain barrier (BBB) integrity, and enhancement of neurovascular function. This multi-target profile highlights the potential of linagliptin as a promising therapeutic candidate for cognitive disorders. Despite encouraging preclinical findings, the CARMELINA and CAROLINA-COGNITION trials found no significant cognitive benefit of linagliptin, highlighting the gap between preclinical evidence and demonstrated clinical efficacy. This narrative review summarizes the molecular mechanisms and preclinical and clinical evidence regarding the effects of linagliptin in cognitive disorders, with particular emphasis on its potential neuroprotective mechanisms and translational challenges.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Hao J, Zhang J, Li Q, et al (2026)

Molecular Mechanisms of Nanoparticle-Mediated Targeted Drug Delivery in Neurodegenerative Diseases.

International journal of nanomedicine, 21:651672.

With global population aging, the incidence of neurodegenerative diseases continues to rise, and the blood-brain barrier (BBB) excludes approximately 98% of small-molecule drugs and nearly all large-molecule biologics from the central nervous system (CNS), so conventional small-molecule pharmacotherapy is largely limited to symptom modulation. Nanodrug delivery systems, including ligand-engineered polymeric, lipid, and inorganic nanoparticles as well as naturally secreted extracellular vesicles, have been proposed as a way to overcome the BBB and modulate disease pathways, and most of the supporting evidence currently derives from rodent models. This review synthesizes the molecular mechanisms by which these systems cross or bypass the BBB, summarizes representative disease-specific interventions in Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, and multiple sclerosis, and critically discusses translational bottlenecks, with the explicit aim of distinguishing established mechanisms from preclinical observations and clarifying the path to clinical investigation. We deliberately limited in scope to systems for which mechanistic and delivery data are available, and the rapid pace of the field means that conclusions about clinical efficacy cannot be drawn from the present preclinical literature. Nevertheless, it still provides valuable insights for research in this field.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Bedel A, Bouaziz-Amar E, Bousiges O, et al (2026)

[The blood biomarker breakthrough in Alzheimer's disease: what applications in 2026? Part II: Emerging blood biomarkers, prospects and current limitations].

Annales de biologie clinique, 84(5):457-479.

This review highlights emerging blood-based biomarkers for Alzheimer's disease (AD) beyond the amyloid and Tau markers currently entering clinical practice. These biomarkers reflect multiple pathophysiological mechanisms involved in AD, including astroglial activation, genetic susceptibility, neuroinflammation, synaptic dysfunction, and neuronal plasticity. The clinical utility of measuring blood levels of GFAP, ApoE4, Apoε4, sTREM2, BDNF, inflammatory cytokines and beta-synuclein in Alzheimer's disease is discussed. Despite encouraging results, none of these biomarkers alone possesses sufficient diagnostic and prognostic value. Further development or their combination into panels will need to be evaluated to determine their potential future use in diagnosis, patient stratification or even therapeutic monitoring in patients with Alzheimer's disease.

RevDate: 2026-11-16

Fan C, Li B, S Wang (2026)

Human milk oligosaccharides as immunomodulators of the gut-immune-brain axis: a potential route to suppressing neuroinflammation in Alzheimer's disease.

Nutritional neuroscience [Epub ahead of print].

BACKGROUND: Alzheimer's disease (AD), the most common cause of dementia, is characterized by interacting pathological processes in which chronic neuroinflammation plays a central role. The gut-brain axis connects intestinal and central nervous system function through immune, neural, and metabolic pathways, yet how immune signaling integrates these pathways in AD remains unclear. Human milk oligosaccharides (HMOs) are structurally diverse bioactive glycans whose immunomodulatory properties extend beyond their prebiotic effects. This narrative review examines HMOs within a gut-immune-brain framework, proposing that neuroinflammation amplifies the interplay between gut-derived immune signals, amyloid-β and tau pathology, and neurodegeneration.

METHODS: Relevant literature was retrieved from PubMed, Web of Science, and Scopus through January 2026. The review focused on English-language publications from 2010 onward, supplemented by earlier foundational studies that provided essential mechanistic or historical context.

RESULTS: We synthesize evidence on immune communication along the gut-brain axis and examine how HMOs may influence this communication through microbiota-dependent effects and direct interactions with immune receptors. Particular attention is given to the relationships between HMO structure, receptor engagement, immune cell responses, and inflammatory signaling. These mechanisms provide a rationale for investigating whether HMOs can modify peripheral immune signals that contribute to neuroinflammation in AD. Throughout the review, findings from infant and other experimental settings are distinguished from evidence directly relevant to aging and AD.

CONCLUSION: Research on HMOs in aging and AD remains insufficient: direct evidence from aged or AD models is scarce, human trials are lacking, infant physiology differs substantially from that of older adults, and the bioavailability of HMOs to the aged brain is still uncertain. We therefore delineate this translational gap and outline research strategies to address it. Collectively, this review provides a conceptual framework for understanding the potential immunoregulatory roles of HMOs in neuroinflammation and identifies them as a hypothesis-generating class of candidate immunomodulators for AD.

RevDate: 2026-11-16

Xu S, Wang Q, Zhou Y, et al (2026)

SVP Maps Spatially Variable Functional Programs and Their Coupling in Spatial Transcriptomics.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) pii:e78741 [Epub ahead of print].

Spatial transcriptomics has made tissue architecture measurable at molecular resolution, yet most computational methods still identify spatially variable genes and infer biology only indirectly. We present SVP, a framework that directly maps spatially variable cell states, pathways and regulatory programs from spatial transcriptomic data. SVP combines location-level functional activity inference with global and local spatial autocorrelation and extends these analyses to bivariate spatial coupling across heterogeneous features. Across simulations and real datasets, SVP recovered cell-state-associated activity patterns at individual captured locations, detected spatially variable features with calibrated statistics, and scaled efficiently to large datasets. In pancreatic ductal adenocarcinoma, SVP identified a spatially co-organized hypoxic and extracellular-matrix-remodeling niche that co-localized with regions of low immune activity. It further captured functional maturation in the developing human heart and plaque-associated glial programs in Alzheimer's disease models. SVP enables direct analysis of functional spatial organization, moving beyond gene-centric descriptions of tissue structure.

RevDate: 2026-11-16

Grant JG, Hunter JM, McMillan TM, et al (2026)

Comparing multivariate cognitive change in unimpaired older adults to those with questionable impairment or mild dementia: a NACC study.

Journal of clinical and experimental neuropsychology [Epub ahead of print].

INTRODUCTION: We explored how frequently unimpaired older adults show declines across multiple cognitive measures and examined the extent to which their rates of multivariate cognitive change compared to older adults with questionable impairment or mild dementia.

METHOD: Two-year change scores were calculated for 1208 participants in the National Alzheimer's Coordinating Center (NACC) database. The number of declines in performance falling below the 5[th] percentile in the natural distribution of change scores (the total change count) among the unimpaired participants (n = 742) was compared to those with questionable impairment (n = 389) and those with mild dementia (n = 77).

RESULTS: Only 9.9% of the cognitively unimpaired participants obtained two or more significant declines in performance, compared to 27.5% of the questionably impaired participants and 49.4% of those with mild dementia. The total change count demonstrated significant discriminative ability for distinguishing between cognitively unimpaired participants and those with questionable impairment (AUC = .621) or mild dementia (AUC = .759). The threshold of two or more declines maintained high specificity (90.1%) for identifying atypical cognitive decline. In a multinomial logistic regression, a change count of two or more was a robust predictor of both questionable impairment (OR = 3.47) and mild dementia (OR = 8.55), beyond the effects of demographic covariates (age, gender, education, race/ethnicity).

CONCLUSIONS: Less than one tenth of cognitively unimpaired older adults show two or more significant declines in their performance on 13 measures from the NACC UDS 3.0 neuropsychological test battery. Individuals who exhibit two or more significant declines in their raw scores across this battery are likely experiencing atypical cognitive decline. Establishing longitudinal base rates of cognitive change across a test battery offers a viable, empirically grounded approach to identifying progression along the dementia continuum.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Chen Z, Zhang B, Liu G, et al (2026)

Systematic Multi-Omics Analysis Reveals Coumestrol as a Dual Modulator of INO80E and LACTB in Alzheimer's Disease.

CNS neuroscience & therapeutics, 32(11):.

OBJECTIVE: To prioritize genetically supported candidate targets for Alzheimer's disease (AD) using an integrative multi-omics framework and to nominate candidate small-molecule compounds with translational potential.

METHODS: Transcriptome-wide association studies (TWAS) were performed by integrating AD genome-wide association study summary statistics with expression quantitative trait locus data from multiple brain regions, whole blood, and single-cell contexts. Multi-marker Analysis of GenoMic Annotation (MAGMA), summary data-based Mendelian randomization (SMR), and Bayesian colocalization analyses were used to further evaluate genetic support for prioritized genes. Single-cell RNA sequencing data from prefrontal cortex samples were analyzed to characterize cell-type expression patterns. Quantitative real-time polymerase chain reaction was conducted in human brain tissues to assess candidate gene expression. Phenome-wide association studies (PheWAS), druggability assessment, and molecular docking were used to explore genetic pleiotropy and nominate candidate compounds. The effects of coumestrol were further examined in PS19-derived primary hippocampal neurons.

RESULTS: Multi-layer TWAS prioritized GIGYF1, LACTB, and INO80E as AD-associated candidate genes, with additional support from MAGMA, SMR, colocalization, single-cell characterization, and human brain tissue validation. PheWAS did not identify broad phenome-wide association signals for LACTB or INO80E in the current dataset. Molecular docking predicted stable interactions between coumestrol and both LACTB and INO80E. In PS19-derived primary hippocampal neurons, coumestrol enhanced cell viability and reduced LACTB and INO80E mRNA expression.

CONCLUSION: This study prioritizes LACTB and INO80E as genetically supported candidate targets for AD and nominates coumestrol as a candidate small molecule requiring further mechanistic and pharmacological validation.

RevDate: 2026-11-16

Chiaravalloti A, Martorana A, Micarelli A, et al (2026)

Cerebello-extracerebellar connectivity and relative FDG uptake in relation to Alzheimer biomarkers and cognitive trajectories.

The neuroradiology journal [Epub ahead of print].

We examined whether a fixed anatomical summary of cerebello-extracerebellar functional connectivity and relative regional fluorodeoxyglucose (FDG) uptake showed convergent associations with Alzheimer biomarkers and subsequent cognition. This exploratory, non-preregistered Alzheimer's Disease Neuroimaging Initiative study averaged 2208 resting-state connections linking 24 cerebellar and 92 extracerebellar regions. A 90-day imaging window yielded 131 participants for global cross-sectional analyses and 126 for regional FDG analyses (123 with complete cerebellar uptake). Four FDG composites used a brainstem reference. Models used heteroscedasticity-robust inference or subject fixed effects with clustered inference for longitudinal clinical and memory trajectories. No principal family survived false-discovery-rate correction: global connectivity, 0/5; regional FDG biomarker, connectivity and longitudinal families, 0/8, 0/4 and 0/8. All 72 regional connectivity and 48 lobular FDG tests were also nonsignificant. Higher tau was nominally associated with lower thalamic uptake (standardized β = -0.231; 95% CI -0.416 to -0.047; p = 0.014; q = 0.114). Additional grey-matter adjustment yielded q = 0.023, a hypothesis-generating sensitivity signal. The findings do not support interpreting these summary measures as compensatory markers in this selected sample. Spatial averaging, limited precision, reference-region dependence, partial-volume effects and linear trajectory assumptions leave smaller, circuit-specific or nonlinear associations unresolved.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Daghini E, Tribble JR, Amato R, et al (2026)

Taurine metabolism: a potential target for neuroprotection in age-related neurodegenerative diseases.

Mammalian genome : official journal of the International Mammalian Genome Society, 38(1):.

Taurine is one of the most abundant free amino acids in mammals and plays essential roles in cellular homeostasis, mitochondrial function, calcium regulation and neuronal survival. Taurine availability varies markedly across tissues, species and sexes, reflecting the balance between endogenous synthesis, dietary intake, transport and efflux. Although reduced taurine levels have been reported in some aging tissues, recent longitudinal studies indicate that circulating taurine does not decline universally with age, and its value as a biomarker of aging remains debated. Alterations in taurine or its transporter SLC6A6 have been described in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease and retinal degenerations. Preclinical studies indicate that taurine supplementation mitigates excitotoxicity, stabilizes mitochondrial function, reduces neuroinflammation and supports myelination and synaptic balance. Despite this strong mechanistic rationale, clinical evidence remains limited and heterogeneous, underscoring the need for biomarker-guided trials and a clearer definition of optimal therapeutic windows. In this review, we summarize the general properties of taurine and its metabolic regulation. We examine taurine's neuroprotective properties across different neurodegenerative conditions and discuss future perspectives for targeting taurine metabolism as a promising but largely unexplored strategy for intervention in age-related neurodegenerative diseases.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Zhang W, Jiang Y, Zhu M, et al (2026)

The emerging role of microglial TREM2 in Alzheimer's Disease: pathogenesis and therapeutic implications.

Molecular biology reports, 53(1):.

Alzheimer's disease (AD), the most common cause of dementia, imposes a substantial and growing burden on families and society. Although AD is classically defined by amyloid and tau pathology, microglial dysfunction is increasingly recognized as a central determinant of disease progression. TREM2 (Triggering Receptor Expressed on Myeloid cells 2), predominantly expressed on microglia, is a key regulator of microglial responses in the AD brain. In this review, we propose that TREM2 functions as a context- and disease-stage-dependent checkpoint that integrates microglial survival, phagocytosis, metabolic adaptation, and inflammatory signaling, thereby shaping AD pathogenesis. This framework helps explain why TREM2 signaling can exert protective or detrimental effects across disease stages and suggests that effective TREM2-directed therapy will require stage-specific modulation rather than simple agonism or inhibition. We critically examine the physiological functions of microglia and TREM2, evaluate TREM2-related biomarkers, and discuss emerging therapeutic strategies, thereby providing a conceptual basis for microglia-targeted AD diagnosis and treatment.

RevDate: 2026-11-16

Chen J, J Tian (2026)

Subcellular proteomics uncovers the link between myelin-axon interface vulnerability and Aβ pathology in Alzheimer's disease.

Science China. Life sciences [Epub ahead of print].

RevDate: 2026-11-16
CmpDate: 2026-11-16

Wang Y, Zhang Y, Wei H, et al (2026)

Integrated Network Toxicology, Machine Learning, and Structural Biology Identify a Candidate Gene Network Linking Predicted Acetyl Tributyl Citrate Targets to Alzheimer's Disease.

Journal of molecular neuroscience : MN, 76(4):.

As a common plasticizer, acetyl tributyl citrate (ATBC) poses a potential public health risk, yet its role in Alzheimer's disease (AD) is unclear. This study seeks to identify candidate molecular links between computationally predicted ATBC targets and AD-associated transcriptional alterations. We combined differential gene expression and co-expression results from two AD-related transcriptomic datasets with in silico ATBC target predictions from ChEMBL, PharmMapper, and SwissTargetPrediction, followed by machine learning feature selection, network toxicology, and molecular docking. We identified sixty-nine overlapping candidate genes shared among AD differentially expressed genes, AD-associated WGCNA modules, and computationally predicted ATBC targets. Among these, three genes-Interferon-stimulated gene 20 kDa (ISG20), Cytochrome P450 26A1 (CYP26A1), and β-1,3-Galactosyltransferase-1 (B3GALT1)-were further prioritized through machine learning. Docking scores were - 5.1 kcal/mol for ISG20, - 5.4 kcal/mol for CYP26A1, and - 4.6 kcal/mol for B3GALT1. These computational results suggest plausible binding poses. Our integrated analysis nominates ISG20, B3GALT1, and CYP26A1 as candidate molecular links between predicted ATBC targets and AD-associated transcriptional changes, providing a computational foundation for experimental validation.

RevDate: 2026-11-16

Bekena S, Singh RK, Pal S, et al (2026)

Sensorimotor impairment and cognitive function across the Alzheimer's disease continuum and major depressive disorder.

GeroScience [Epub ahead of print].

Sensorimotor impairments are associated with cognitive decline, but their cumulative burden across clinical subgroups is not well characterized. To test whether sensorimotor burden is associated with baseline cognition and modifies subgroup-related cognitive differences. We analyzed 511 community-dwelling older adults. Participants were classified as cognitively normal, preclinical Alzheimer's disease (Clinical Dementia Rating score of 0 with amyloid positron-emission tomography positivity), mild cognitive impairment, or major depressive disorder. Cognition was measured with the Preclinical Alzheimer Cognitive Composite. A Sensorimotor Index summed impairments in grip strength, gait speed, reaction time, hearing, vision, and olfaction and was categorized as low (0-1) or elevated (≥ 2). Multivariable linear regression assessed subgroup, index, and subgroup-by-index terms, adjusting for age, sex, race, education, apolipoprotein E ε4 status, and neighborhood deprivation. Without interactions, elevated burden was associated with lower cognitive scores (β =- 0.374; 95% confidence interval, - 0.508 to - 0.240; p < 0.001). In the interaction model, the mild cognitive impairment-by-elevated-index (β =- 0.647; 95% confidence interval, - 0.981 to - 0.313; p < 0.001) and major depressive disorder-by-elevated-index terms (β =- 0.440; 95% confidence interval, - 0.759 to - 0.120; p = 0.007) were significant; the preclinical Alzheimer's disease interaction was not. Dose-response analyses showed progressively lower cognitive scores at higher index levels. Greater sensorimotor burden was associated with lower cognition, with stronger adverse associations in mild cognitive impairment and major depressive disorder. Multidomain sensorimotor assessment may improve characterization of cognitive heterogeneity in older adults.

RevDate: 2026-11-16

Mao E, Lin S, Prasad N, et al (2026)

Design Strategies in Discrete Choice Experiments for Individuals with Cognitive Impairment: A Systematic Review.

The patient [Epub ahead of print].

OBJECTIVES: Patient preference evidence is increasingly important for value assessment and decision making in Alzheimer's disease and related dementias (ADRD). Discrete choice experiments (DCEs) are widely used to elicit patient preferences but may raise feasibility concerns in individuals with cognitive impairment. We aimed to systematically review studies that explicitly evaluated design choices in DCEs for preference elicitation in individuals with cognitive impairment.

METHODS: We systematically searched PubMed, Embase, and CINAHL/PsycINFO through January 23, 2026 for studies that evaluated DCE design adaptations or feasibility in cognitively impaired populations. Findings were synthesized narratively according to adaptations and their reported effects on comprehension, task performance, and respondent burden.

RESULTS: We identified six studies. Four categories of design adaptations were identified: attribute description, simplification of choice task structure, visual design and layout, and survey administration. We learned that attribute familiarity and concreteness improved understanding; respondents struggled when the status-quo state was not anchored to their own current health state. Limiting to three options per task and three attributes per option improved completion rates. Greater overlap in attribute levels across options made tasks easier to complete. Use of icons as illustrations improved attribute comprehension, and caregiver involvement in interviewer-administered surveys aided completion.

CONCLUSIONS: Existing evidence suggests that DCEs can be successfully completed by individuals with mild cognitive impairment or early-stage dementia when tasks are appropriately adapted to lessen complexity. However, the evidence base remains limited. Additional methodological research is needed to identify design strategies that improve accessibility of these tasks to those with cognitive challenges while generating meaningful preference information.

RevDate: 2026-11-16

Ketchum FB, Sanford C, Buckingham W, et al (2026)

Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure.

JAMA neurology pii:2856724 [Epub ahead of print].

RevDate: 2026-11-16

Algeciras-Schimnich A, Hu M, Weigand SD, et al (2026)

Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4.

JAMA neurology pii:2856722 [Epub ahead of print].

IMPORTANCE: Alzheimer disease (AD) pathology can be detected years before symptom onset, but some individuals who are biomarker positive and cognitively unimpaired (CU) remain asymptomatic.

OBJECTIVE: To estimate 5- and 10-year absolute risks of mild cognitive impairment (MCI) and dementia using continuous plasma phosphorylated tau 217 (p-tau217) and p-tau217/amyloid β 42 (Aβ42).

This cohort study included participants from the Mayo Clinic Study of Aging (MCSA) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants were CU individuals aged 60 to 90 years with baseline Fujirebio Lumipulse plasma p-tau217 measurements, APOE genotyping, and longitudinal clinical follow-up. The MCSA is a population-based longitudinal cohort of residents in Olmsted County, Minnesota; ADNI is a multicenter observational cohort. MCSA data were ascertained from October 2008 to September 2025; ADNI data from September 2005 to January 2026.

EXPOSURES: Age, sex, APOE ε4, p-tau217, and p-tau217/Aβ42.

MAIN OUTCOMES AND MEASURES: Transition from CU to MCI and dementia estimated using continuous-time multistate models.

RESULTS: In the MCSA cohort (n = 1644), the median (IQR) age was 72 (66-79) years; 804 participants (49%) were female and 840 (51%) were male. In the ADNI cohort (n = 534), the median (IQR) age was 72 (68-77) years; 297 participants (56%) were female and 237 (44%) were male. A p-tau217 of 0.324 pg/mL vs 0.072 pg/mL (90th vs 10th percentile) was associated with 2.66 (95% CI, 2.02-3.51), 3.02 (95% CI, 2.21-4.12), 2.62 (95% CI, 1.99-3.46), and 2.79 (95% CI, 2.04-3.81) greater hazard of clinical progression in MCSA female participants who did not carry the APOE ε4 variant (ε4-), females who did carry the APOE ε4 variant (ε4+), males who were ε4-, and males who were ε4+, respectively. In ADNI, hazards were 2.67 (95% CI, 1.86-3.85), 2.83 (95% CI, 1.89-4.22), 2.08 (95% CI, 1.48-2.92), and 3.99 (95% CI, 2.59-6.13), respectively. In MCSA, higher baseline p-tau217 and older age were associated with greater absolute risk of progression. At age 75 years and assuming sex and APOE are at the MCSA means of 0.511 and 0.268, 5-year absolute risk of MCI increased from 7% (95% CI, 5%-8%) to 17% (95% CI, 13%-20%) for a p-tau217 concentration of 0.072 vs 0.324 pg/mL; 10-year absolute risk of MCI increased from 15% (95% CI, 12%-18%) to 35% (95% CI, 29%-41%; P < .001 for both). At 0.324 pg/mL, 5-year MCI risk increased from 6% (95% CI, 4%-8%) to 37% (95% CI, 32%-43%) for ages 65 to 85 years; 10-year risks were 17% (95% CI, 12%-21%) and 66% (95% CI, 57%-74%; P < .001 for both). Results were similar for p-tau217/Aβ42.

CONCLUSIONS AND RELEVANCE: This study found that higher plasma p-tau217 and older age were associated with higher 5- and 10-year risk of cognitive impairment. Plasma p-tau217 concentrations, combined with age, sex, and APOE ε4 status, can enable individualized estimation of short-term absolute risk of cognitive impairment in CU individuals, with applications in prognosis and trial enrichment in preclinical AD.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Bayart JL, Villain N, Planche V, et al (2026)

Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments.

Neurology, 107(11):e218784.

BACKGROUND AND OBJECTIVES: Blood-based biomarkers (BBMs), especially plasma tau phosphorylated at threonine 217 (p-tau217), could scale Alzheimer disease (AD) clinical-biological diagnosis, but clinical use requires thresholds transferable across laboratories and populations. We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results.

METHODS: This multicenter, cross-sectional diagnostic-classification study included an exploratory Brussels cohort and 3 external validation cohorts. Brussels participants were cognitively unimpaired or impaired and had Aβ status determined by amyloid-PET or CSF Aβ42 and tau status by tau-PET or CSF p-tau181. Validation cohorts comprised consecutive Paris memory-clinic patients, patients with early-onset neurodegenerative dementia in Bordeaux, and individuals with monogenic frontotemporal lobar degeneration (FTLD). Plasma p-tau217 was measured locally on Lumipulse analyzers. BBMs and ratios were compared using receiver operating characteristic (ROC) analyses. In Brussels, a Youden cutoff and dual 95% or 97.5% sensitivity/specificity cutoffs were derived; intermediate values defined gray zones.

RESULTS: Among 411 participants (mean age 70.5 years; 51.6% female), p-tau217 showed the best diagnostic performance; p-tau217/Aβ42 did not improve performance or reduce gray zones. In Brussels, p-tau217 discriminated Aβ+ from Aβ- status (AUC 0.96, 95% CI 0.93-0.98; p < 0.0001). The 0.193 pg/mL Youden cutoff (95% CI 0.178-0.213) yielded 91.5% sensitivity (95% CI 84.7-95.5) and 91.6% specificity (95% CI 84.8-95.5) and detected neocortical tau-PET positivity with 98.5% sensitivity and 81.8% specificity. In Paris, sensitivity/specificity for clinical-biological AD were 93.2% (95% CI 85.1-97.1)/93.0% (95% CI 81.4-97.6); in Bordeaux, sensitivity/specificity for clinical-biological AD were 95.7% (95% CI 79.0-99.2)/92.3% (95% CI 66.7-98.6). Specificity in monogenic FTLD was 88.4% (95% CI 75.5-94.9). False-positive classifications were enriched in FTLD with amyotrophic lateral sclerosis (ALS). Dual thresholds yielded gray zones in 15.4%-24.8% of Paris patients; second-line CSF testing resolved 86.2%-88.9% of gray zone cases.

DISCUSSION: Lumipulse plasma p-tau217 thresholds were transferable across centers, analyzers, reagent lots, and heterogeneous clinical populations, supporting evaluation of plasma-first pathways with confirmatory testing for gray zone values. Values below 0.193 pg/mL made neocortical tauopathy unlikely. Limitations include cross-sectional design, specialized Western European recruitment, unavailable race/ethnicity data, heterogeneous reference standards, incomplete AD copathology adjudication in monogenic FTLD, and no cross-platform comparison.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Weber SK, Farris CM, Ma Y, et al (2026)

Identification of Type 1 and Type 2 α-Synuclein-Seeds by CSF Seed Amplification Assay in Patients With Movement Disorders.

Neurology, 107(11):e218763.

BACKGROUND AND OBJECTIVES: A novel α-synuclein (syn) seed amplification assay (synSAA) differentiates 2 types of syn-seeds in CSF: type1, associated with Lewy bodies (LBs), and type2, associated with glial-cytoplasmic inclusions, the hallmark of multiple system atrophy (MSA). However, syn-copathology extends beyond synucleinopathies, and copathologies are increasingly relevant. Different syn-seeds have been assessed in highly characterized research cohorts, but data assessing type and frequency in patients from routine clinical encounters are lacking. Hence, our objective was to determine frequency, type, and clinical association of different syn-seeds in CSF in a large cohort from a movement disorders (MDs) clinic.

METHODS: This cross-sectional study included consecutive patients from a MD clinic between 2009 and 2025. CSF was tested with synSAA and clinical data derived from medical records.

RESULTS: We recruited 1,059 patients (mean age 70.5 ± 10.5 years; 38.4% female; mean disease duration 4.0 ± 4.6 years). Syn-seeds were detected in 54.2% of patients, with type1-seeds predominating (88.5%). High synSAA positivity was observed in Parkinson disease (PD) (84.7%), dementia with LB (93.4%), MSA (84.5%), isolated REM-sleep behavior disorder (iRBD) (80.0%), and normal pressure hydrocephalus (NPH) with PD (87.0%). Undetermined hypokinetic MD showed 53.7% positivity. Moderate proportions (∼25-33%) were detected in Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal syndrome, and idiopathic NPH without PD, while other neurologic disorders showed 20.9% positivity. Type2-seeds were the major seed type in MSA (79.6% of syn-seeds) and minor type in PD (6.2%), PSP (9.1%), and undetermined hypokinetic MD (13.8%). Overall, type2-seeds were present in only 2.6% of non-MSA patients. Patients with type1-seeds had worse olfaction and more hallucinations. Multivariable regression identified impaired olfaction (OR = 0.67 per point increase of identified smells out of 12, higher scores indicating better olfaction) significantly associated with type1-seeds.

DISCUSSION: Our results provide reference data on syn-seed frequency in routine clinical patients, demonstrating that type1-seeds indicate common underlying syn-pathology or copathology associated with hyposmia and hallucinations. Type2-seeds are specific to MSA and detection of type2-seeds outside the clinical MSA spectrum can improve diagnosis of patients with atypical presentations because our results match neuropathologic MSA studies. In vivo identification of different seed types will improve diagnosis, clinical trial stratification, and development of targeted therapies.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Pezzoli S, Oddi AP, Blazhenets G, et al (2026)

APOE Genotype and Amyloid PET in People With Mild Cognitive Impairment or Dementia: Results from Clinical Practice.

Neurology, 107(11):e218689.

BACKGROUND AND OBJECTIVES: APOE genotype is the strongest genetic risk factor for sporadic Alzheimer disease, but evidence on its utility in clinical practice is limited. We evaluated the predictive value of APOE genotype for PET-measured amyloid positivity and global amyloid burden in older adults with cognitive impairment evaluated in memory clinics as part of their clinical care. We also examined associations between APOE genotype and clinical presentation, including impairment level (mild cognitive impairment [MCI] or dementia) and MCI type (amnestic or nonamnestic).

METHODS: This observational multicenter study included Medicare beneficiaries with MCI or dementia from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, who were coenrolled in the Amyloid Neuroimaging and Genetics Initiative (ANGI). Participants underwent amyloid PET and APOE genotyping. Amyloid status was determined using local visual reads and a Centiloid threshold (24.4). Logistic regression assessed associations between APOE genotype and amyloid positivity. Analysis of covariance models assessed differences in global amyloid burden (Centiloids) across genotypes. Voxel-wise analyses examined regional tracer uptake.

RESULTS: The study included 1,641 participants (mean [SD] age, 74.3 [5.6] years; 43.6% female), of whom 1,219 had MCI and 422 had dementia. APOE2/4, APOE3/4, and APOE4/4 genotypes had progressively higher odds of visual reads-based amyloid positivity compared with APOE3/3 (APOE2/4, OR = 3.10, 95% CI [1.58-6.47], p = 0.002; APOE3/4, OR = 4.52, 95% CI [3.50-5.86], p < 0.001; APOE4/4, OR = 26.34, 95% CI [12.93-63.39], p < 0.001). The results were similar when scan positivity was defined by a Centiloid threshold. Amyloid burden increased progressively across APOE genotypes, with higher-risk genotypes (APOE3/4 and APOE4/4) showing the highest Centiloids (p < 0.001, partial η[2] = 0.20). Among amyloid-positive participants, APOE4 genotype was associated with increased tracer uptake across posterior cingulate, precuneus, medial frontal, temporoparietal, and lateral frontal cortices in a dose-dependent manner, whereas APOE2 genotype showed a more focal distribution. A significant APOE3/4-by-sex interaction indicated higher odds of visual reads-based amyloid positivity in APOE3/4 women. Clinically, APOE4/4 was associated with dementia and amnestic MCI.

DISCUSSION: APOE4 genotype was associated with both amyloid PET positivity and quantitative amyloid burden, following a dose-dependent gradient. These findings extend evidence linking APOE genotype to amyloid pathology in clinical settings. Limitations include restriction to cognitively impaired individuals and limited racial and ethnic diversity.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Aali A, Schaffner S, Lam JST, et al (2026)

The Burden of Neurologic Disorders in Canada, 1990-2023: A Systematic Analysis in the Global Burden of Disease Study 2023.

Neurology, 107(11):e218702.

BACKGROUND AND OBJECTIVES: Neurologic disorders are leading contributors to global disability and mortality, yet Canada-specific burden estimates have not been updated with the most recent Global Burden of Disease (GBD) data. We aimed to quantify the burden of 18 neurologic conditions in Canada in 2023, characterize trends from 1990 to 2023, describe age-specific and sex-specific patterns, and compare Canada with the high-income country average.

METHODS: This retrospective epidemiologic modeling study analyzed GBD 2023 data for Canada. Eighteen conditions whose primary health loss manifestation directly affects the central or peripheral nervous system were included. Outcome measures included prevalence, mortality, and disability-adjusted life years (DALYs) comprising years lived with disability (YLDs) and years of life lost (YLL). Age-standardized rates are all per 100,000 population. 95% uncertainty intervals (UI) are reported for all estimates.

RESULTS: Modeling evaluated the entire Canadian population across 34 years. In 2023, neurologic disorders accounted for 11.48% (UI: 9.47-14.26) of total DALYs and 16.31% (UI: 10.56-26.24) of deaths. Burden was heavily driven by nonfatal disability metrics (YLDs); Alzheimer disease and other dementias led absolute DALYs at 366,548.5 (UI: 180,491.8-710,281.4), followed by migraine at 232,619.5 (UI: 151,390.4-320,391.1) and ischemic stroke at 223,748.0 (UI: 194,981.3-249,309.6). Migraine led age-standardized DALY rates at 565.8 (UI: 374.0-783.1) per 100,000, driven entirely by nonfatal disability metrics. Dementias drove mortality with 20,108.6 (UI: 4,999.6-50,266.6) deaths. From 1990 to 2023, the steepest age-standardized DALY rate increases occurred in other neurologic disorders (153.6% [UI: 129.0-185.1]), encephalitis (59.2% [UI: 25.1-95.6]), and Parkinson disease (25.4% [UI: 18.9-33.0]), while meningitis declined by 62.6% (UI: 57.4-66.9).

DISCUSSION: Neurologic disorders present a substantial public health challenge in Canada, marked by widespread midlife nonfatal disability from migraine and escalating late-life neurodegeneration. Over 3 decades, the national burden shifted toward chronic neurodegenerative diseases. These findings highlight the need for national strategies to expand care capacity and address chronic disability. A key limitation of this analysis is that GBD estimates for Canada are currently restricted to the national level; because Canada is a vast, geographically and demographically diverse nation, country-wide aggregates do not elucidate critical subnational disparities.

RevDate: 2026-11-16

Pichet Binette A (2026)

From Research Cohorts to Clinical Practice: Bringing Alzheimer Disease Genetic and Biomarker Discoveries Into the Memory Clinic.

Neurology, 107(11):e218748.

RevDate: 2026-11-16

Li X, Xu H, Zhang Y, et al (2026)

Cellular Senescence and White-Matter Injury: A Proposed Glial Cascade in AD and Cerebral SVD.

Aging and disease pii:AD.2026.1063 [Epub ahead of print].

Cellular senescence is one of the hallmarks of aging and has been implicated in age-related neurological disorders, including Alzheimer's disease (AD) and cerebral small-vessel disease (SVD). AD and SVD frequently coexist and both become more common with age, so an age-dependent mechanism may contribute to both. Although their upstream pathologies differ, both can damage white matter. This review proposes a cascade in which microglial senescence may sustain inflammation in white matter and impair myelin debris clearance. In this environment, oligodendrocyte precursor cells (OPCs) may differentiate poorly, limiting remyelination, while senescence-like changes within these cells may compound this deficit. Senescent brain endothelial cells may also damage white matter through blood-brain barrier disruption, microvascular rarefaction, reduced perfusion, and impaired neurovascular coupling. Because barrier leakage activates microglia and poor perfusion may limit metabolic support to the oligodendrocyte lineage, these vascular changes could aggravate glial dysfunction. This review integrates evidence scattered across different models and diseases, examining each link in the proposed cascade in turn. The full sequence has not yet been demonstrated in a single experimental system or in humans. In animal models, eliminating or modulating senescent cells has improved pathology or cognition, and restoring aged OPC function has enhanced remyelination. In people, senolytic trials have assessed safety and drug exposure but have not yet established clinical benefit. White-matter injury may serve as a measurable endpoint shared by AD and SVD, and cellular senescence remains a potential contributor to this injury.

RevDate: 2026-11-16

Wang X, Lv A, Tian Y, et al (2026)

The Microglial Lipid-Immune Axis in Brain Aging: Adaptive Lipid Handling and Metabolic Dysfunction in Lipid-Droplet-Accumulating Microglia.

Aging and disease pii:AD.2026.1294 [Epub ahead of print].

Microglia in the aging brain process lipids released during membrane and myelin turnover. Lipid droplets can buffer this demand, but lipid retention also accompanies defective phagocytosis and inflammatory responses. This review critically compares the substrates, perturbations, and functional endpoints underlying these observations. We examine cholesterol esterification and export, fatty-acid activation and triacylglycerol synthesis, and lipid mobilization through lipolysis and lipophagy in relation to TREM2-TYROBP/DAP12-SYK signaling, APOE genotype, and local substrate supply. Physiological-aging studies are distinguished from demyelination, Alzheimer's disease, and Parkinson's disease models. Quantitative comparisons show why inhibiting storage can improve selected amyloid-associated phenotypes while impaired storage can compromise myelin repair. We use the established distinction between lipid pools and metabolic flux to assess what each experiment demonstrates: altered droplet abundance, a specific processing defect, or recovery of a cellular task. We propose a reporting framework covering droplet burden, transcriptional state, metabolic function, and cellular performance, with missing measurements retained explicitly and no claim of validated diagnostic thresholds. Intervention evidence is assessed by the reaction perturbed, dose and duration, target validation, delivery route, and measured benefit. The resulting synthesis identifies supported mechanisms and unresolved causal steps, providing a practical basis for selecting and evaluating interventions without treating droplet reduction as a universal therapeutic endpoint.

RevDate: 2026-11-16

Zhang W, Hu Q, Ding M, et al (2026)

Toward Closed-Loop Cognitive Modulation in Alzheimer's Disease: BCI-Relevant Evidence and a Translational Roadmap.

Aging and disease pii:AD.2026.11026 [Epub ahead of print].

Alzheimer's disease (AD) has entered a biomarker-defined era, yet most cognitive and neuromodulatory interventions continue to use fixed targets, timing, and doses. This targeted narrative review maps brain-computer interface (BCI) and closed-loop-relevant evidence in AD and mild cognitive impairment (MCI) by examining how sensing, control, and intervention modules are used prospectively. Read modules include electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), real-time functional magnetic resonance imaging (fMRI), functional ultrasound (fUS) and transcranial ultrasound localization microscopy (t-ULM), and digital measures. Control functions include feature extraction, within-person state decoding, uncertainty-aware decision rules, target-engagement assessment, and safety oversight. Write modules include neurofeedback, sensory gamma and sleep-phase acoustic stimulation, transcranial alternating-current stimulation (tACS), transcranial direct-current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), transcranial pulse stimulation (TPS), transcranial ultrasound stimulation (TUS), transcranial photobiomodulation (tPBM), and focused ultrasound-mediated blood-brain barrier (FUS-BBB) opening. Human studies have separately demonstrated signal-contingent feedback, individualized targeting, physiological target engagement, home delivery, and emerging sensing, while preclinical studies provide mechanistic support for gamma, optical, and ultrasound approaches. Sleep-phase acoustic stimulation additionally demonstrates early automated signal-to-stimulus control. Passive sensing provides observations, personalization sets baseline parameters, state-informed control uses current signals to alter delivery, and target engagement verifies the proximal response without establishing clinical efficacy. Reliable decoding of waking cognitive states, broader controller utility, and durable clinical benefit remain unvalidated. We therefore organize the field around disease context, state sensing, feature extraction, state decoding, bounded decision/intervention, response verification, and safety oversight. The decisive early design compares assignments to an adaptive policy with otherwise matched fixed delivery; a sham arm can additionally test intervention efficacy. Such trials must prespecify decoder calibration, uncertainty, abstention, safety limits, and mechanistic and clinical endpoints. Closed-loop cognitive modulation therefore defines a translational research agenda for AD.

RevDate: 2026-11-16

Brum WS, Janelidze S, Singh A, et al (2026)

A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology.

JAMA pii:2856953 [Epub ahead of print].

IMPORTANCE: Blood biomarkers that reflect neurofibrillary tau burden, a defining hallmark of Alzheimer disease (AD), remain limited. Endogenously cleaved microtubule-binding region tau 243 (eMTBR-tau243) has shown promise when measured by mass spectrometry; a scalable immunoassay could broaden research access and support clinical evaluation.

OBJECTIVE: To determine whether plasma levels of eMTBR-tau measured by a novel immunoassay are associated with tau neurofibrillary tangle pathology defined by neuropathology and tau positron emission tomography (PET).

This cross-sectional study included brain donors with antemortem plasma from 2 US autopsy cohorts, and individuals with plasma samples and tau PET from 2 imaging cohorts in Canada and Sweden, with visits between 2002 and 2025 depending on the cohort.

EXPOSURES: Plasma eMTBR-tau measured with an immunoassay and eMTBR-tau243 measured with mass spectrometry.

MAIN OUTCOMES AND MEASURES: Plasma eMTBR-tau levels across neuropathologic Braak neurofibrillary tangle stages (I-VI, ranging from tangles confined to the entorhinal region to widespread neocortical tangles) and tau-PET Braak stages (0-VI), expressed as fold changes. Correlations with regional tau-PET standardized uptake value ratios (SUVRs; higher values indicating more tau tangles), discrimination of regional tau-PET positivity (area under the curve [AUC]), and correlation with mass spectrometry-based eMTBR-tau243.

RESULTS: The study included 728 participants in 4 cohorts (median age by cohort, 71.0-83.5 years; 41.3%-56.6% female). In the 2 autopsy cohorts (n = 241 and n = 240), eMTBR-tau age- and sex-adjusted geometric means were 0.0021 pg/mL and 0.0040 pg/mL, respectively, at Braak stages I-II vs 0.107 pg/mL and 0.101 pg/mL at Braak stage VI (50.5-fold [95% CI, 26.3-97.0] and 25.2-fold [95% CI, 15.8-40.3] higher for stage VI vs stages I-II; P < .001 for both cohorts). In one imaging cohort (n = 99), compared with tau-PET Braak stage 0, eMTBR-tau levels were 11.0-fold (95% CI, 6.9-17.5) higher at stages III-IV and 59.9-fold (95% CI, 39.5-90.7) higher at stages V-VI. Among participants positive for amyloid-β (Aβ) in another imaging cohort (n = 50), the Spearman rank correlations for eMTBR-tau with tau-PET SUVRs were ρ = 0.52 (95% CI, 0.28-0.70) in Braak regions I-II, 0.76 (95% CI, 0.61-0.86) in regions III-IV, and 0.85 (95% CI, 0.75-0.91) in regions V-VI (all P < .001). Immunoassay and mass spectrometry measurements were strongly correlated (Spearman rank correlation, ρ = 0.93 in all participants [n = 108] and ρ = 0.96 in Aβ-positive participants [n = 54]) and discriminated tau-PET positivity similarly (n = 102; AUC range, 0.96-0.99 for the immunoassay and 0.97-0.99 for mass spectrometry).

CONCLUSIONS AND RELEVANCE: A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.

RevDate: 2026-11-16

Tran SD, Yoon HJ, Gahm JK, et al (2026)

ASAM: Adaptive cortical surface representation via dynamic local aggregation and hybrid Attention-Mamba global modeling.

Medical image analysis, 116:104394 pii:S1361-8415(26)00463-9 [Epub ahead of print].

Accurately modeling cortical surface geometry from structural MRI is essential for advancing neuroimaging analysis and biomarker discovery. Recent advances in Transformer and Mamba architectures have shown promise in brain surface modeling by effectively capturing complex feature dependencies. However, they typically rely on fixed or absent neighborhood structures, substantially limiting their ability to represent localized cortical variations. Transformers also incur high computational costs, whereas Mamba lacks explicit mechanisms for encoding local spatial context on non-Euclidean domains. To address these limitations and leverage the complementary strengths of both architectures, we propose ASAM (Adaptive Surface representation with Attention and Mamba), a hybrid framework integrating Transformer and Mamba mechanisms within a parallel architecture. ASAM introduces two novel modules designed specifically for cortical surfaces: Dynamic Multi-Hop Selection (DMHS), which adaptively determines optimal receptive fields for each cortical patch, and Dynamic Feature Merging (DFM), which constructs context-sensitive adjacency matrices from geodesic distances and learned affinities. Extensive evaluations on public neuroimaging datasets demonstrate that ASAM achieves superior or highly competitive performance compared to state-of-the-art Transformer- and Mamba-based baselines in CN vs. MCI classification on ADNI and cross-dataset brain age prediction. By dynamically adjusting neighborhood scales, ASAM yields enriched, geometry-aware cortical surface representations, supporting neuroimaging research on risk stratification and developmental brain assessments while motivating further multi-center validation toward clinical translation. Implementation code is publicly available at: https://github.com/sydat2701/ASAM_surface.git.

RevDate: 2026-11-16

Xu K, He X, Zhang T, et al (2026)

Discovery of multifunctional coumarin-benzylpiperidine hybrids combining acetylcholinesterase inhibition with attenuation of tau hyperphosphorylation for Alzheimer's disease.

European journal of medicinal chemistry, 322:119535 pii:S0223-5234(26)00980-3 [Epub ahead of print].

Alzheimer's disease (AD) arises from complex multifactorial pathologies, highlighting the potential of multifunctional agents for therapeutic intervention. Herein, 42 coumarin-benzylpiperidine hybrids were designed and synthesized to integrate acetylcholinesterase (AChE) inhibition with modulation of tau-associated pathology. The lead compound KZ18 exhibited potent AChE inhibitory activity against eeAChE (IC50 = 0.148 μM) and hAChE (IC50 = 0.105 μM). Molecular docking suggested a binding mode spanning the catalytic active site and peripheral anionic site of AChE. KZ18 was classified as CNS+ in the experimental PAMPA-BBB assay. In okadaic acid-challenged SH-SY5Y cells, KZ18 improved cell viability, reduced intracellular reactive oxygen species accumulation, and attenuated tau phosphorylation at Ser202/Thr205 and Ser396, accompanied by restoration of GSK3β Ser9 phosphorylation. Moreover, oral administration of KZ18 ameliorated scopolamine-induced deficits in spatial working memory, learning, and memory retention, while attenuating hippocampal neuronal damage and astrocyte reactivity. These findings identify KZ18 as a potential multifunctional lead for further anti-AD drug development.

RevDate: 2026-11-16

Rezaei Z, Torabi R, Ryait H, et al (2026)

Foraging reveals systematic suboptimality that is amplified in a mouse model of Alzheimer disease.

Behavioural brain research pii:S0166-4328(26)00547-4 [Epub ahead of print].

Adaptive decision-making extends beyond selecting among discrete alternatives. It requires the dynamic organization of actions as costs, opportunities, and goals evolve over time. Foraging captures this complexity in an evolutionarily conserved behavior that integrates spatial, temporal, and reward-related information across successive actions. These demands make foraging an ecologically grounded framework for investigating Alzheimer disease, in which spatial cognition, temporal organization, cost evaluation, and behavioral flexibility are frequently disrupted. We examined foraging-related action selection in control C57BL/6J mice and APP[NL-G-F] knock-in mice using a controlled task in which travel distance, food texture, and pellet size altered the costs and benefits of available strategies. Bayesian multinomial modeling showed that control mice flexibly redistributed their behavior across conditions, whereas APP[NL-G-F] mice showed impaired cost integration, increased withdrawal, and reduced behavioral flexibility rather than a generalized performance impairment. Comparison with a classical reward-rate-maximization benchmark revealed substantial suboptimality in both groups. Control mice selected the rate-maximizing behavior on 53% of trials, compared with 45% in APP[NL-G-F] mice and exhibited lower regret. These systematic departures suggest that behavior was shaped by cognitive, motivational, or contextual constraints not represented in the normative model, with Alzheimer-disease-relevant dysfunction associated with greater suboptimality. Group differences were greatest when optimal behavior was highly sensitive to competing costs. By preserving the distribution of behavior across strategies, this study establishes foraging-related action selection as a framework for detecting disease-associated disruptions that may be obscured by conventional measures of choice or overall task performance.

RevDate: 2026-11-16

Zhou T, Xu Y, Zhou Q, et al (2026)

RVG29-modified reduction-responsive nanomicelles for brain-targeted delivery of a glutaminyl cyclase inhibitor in Alzheimer's disease.

International journal of pharmaceutics pii:S0378-5173(26)01143-9 [Epub ahead of print].

Although glutaminyl cyclase (QC)-mediated formation of pyroglutamate-modified amyloid-β (pE-Aβ) has been implicated as an upstream pathological event in Alzheimer's disease (AD), the therapeutic translation of small-molecule QC inhibitors remains limited by insufficient brain exposure. Here, we developed a reduction-responsive polymeric micellar platform (designated PIC) based on poly(ethylene glycol) (PEG)-poly(aspartic acid) (PAsp)-poly(valine) (PVal) copolymers. This platform was functionalized with rabies virus glycoprotein-derived peptide 29 (RVG29) to obtain RVG29-PIC-B13 for enhanced brain delivery of B13, an imidazole-based QC inhibitor, and release of its active thiol form. B13 was conjugated to PEG-PAsp-PVal micelles through a disulfide linker, whereas RVG29 was introduced as a brain-targeting ligand to enhance blood-brain barrier transport. RVG29-PIC-B13 formed spherical nanomicelles with an average diameter of 169.9 nm, a drug-loading content of 6.2%, high colloidal stability, and glutathione-triggered release of B13-SH, which retained QC inhibitory activity with an IC50 of 1.17 μM. RVG29 modification significantly enhanced cellular uptake in bEND.3, PC12, and SH-SY5Y cells, increased transport across a bEND.3 monolayer by 3.12-fold, and elevated brain fluorescence accumulation in vivo by 2.58-fold and 1.96-fold compared with free Cy5 and unmodified micelles, respectively. In 8-month-old 3 × Tg-AD mice, 45-day administration of RVG29-PIC-B13 significantly improved performance in the Morris water maze, Y-maze, open-field, and elevated plus maze assays. Mechanistically, RVG29-PIC-B13 inhibited brain QC activity without markedly altering QC expression, reduced Aβ and pE-Aβ burden, attenuated AT8/AT100-associated tau phosphorylation, and preserved dendritic complexity and spine density. Preliminary hematological and histological analyses indicated acceptable biocompatibility. These findings support RVG29-PIC-B13 as a promising reduction-responsive nanodelivery strategy for enhancing brain delivery of QC inhibitors and improving therapeutic outcomes in AD.

RevDate: 2026-11-14

Huang J, Wan H, Jiang W, et al (2026)

EEG Microstate Alterations and Their Association with Cognitive Performance in Late-Onset Epilepsy of Unknown Etiology: Comparison with Alzheimer's Disease.

Brain research bulletin pii:S0361-9230(26)00507-1 [Epub ahead of print].

BACKGROUND: Cognitive impairment is common in late-onset epilepsy of unknown etiology (LOEU), but its electrophysiological correlates and relationship to Alzheimer's disease (AD) remain unclear. We compared resting-state electroencephalogram (EEG) microstate dynamics among LOEU, AD, and cognitively normal (CN) groups and examined their associations with cognitive performance.

METHODS: Eyes-closed 32-channel resting-state EEG recordings were analyzed from 60 patients with LOEU, 65 with AD, and 60 CN participants. Four canonical microstate classes (A-D) were identified. Group differences in microstate parameters were tested with false discovery rate correction. Associations with Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) scores were examined using multivariable interaction models adjusted for age, sex, education, and cerebral small vessel disease burden.

RESULTS: Microstate B duration was longer in LOEU and AD than in CN (Holm-adjusted p=0.011 and 0.016), whereas microstate C occurrence was lower in both patient groups (p=0.001 and 0.018). Microstate D duration was longer in LOEU than in CN and AD (both p=0.038). For microstate A duration, the group interaction survived false discovery rate correction for MMSE (q=0.0255) but not MoCA (q=0.122). In LOEU, longer microstate A duration was associated with lower MoCA and MMSE scores. Pairwise slope comparisons were more negative in LOEU than in CN for both outcomes, whereas LOEU-AD slope differences were not significant.

CONCLUSIONS: LOEU showed altered resting-state EEG microstate dynamics that partly overlapped with those observed in AD, alongside a group difference in microstate D duration. Microstate A duration was associated with cognitive performance in LOEU, although this association did not significantly differ from that observed in AD. These findings support further investigation of EEG microstates as electrophysiological correlates of cognitive dysfunction in LOEU while also highlighting overlap with AD.

RevDate: 2026-11-14

Lee EY, Park J, Lee J, et al (2026)

DEGORA: turning heterogeneous published DEG summaries into an inspectable gene-evidence atlas.

Methods (San Diego, Calif.) pii:S1046-2023(26)00227-6 [Epub ahead of print].

Published tables of differentially expressed genes (DEG tables) can support secondary transcriptomic analyses when expression matrices or variance estimates are unavailable, but they are not consistently deposited in public repositories. DEGORA converts curated DEG tables into a local database that links gene-level evidence to original studies. It standardizes gene identifiers, collapses related contrasts within studies so that each study contributes once, applies fixed heuristic quality weights, and ranks genes by cross-study support and directional concordance. An optional search module identifies potentially reusable tables. We evaluated DEGORA using four human transcriptional programs as positive-control benchmarks, each represented by 2 to 15 publication-level source units and by up to 20 after human microarray sources were added. DEG tables for three programs were generated from publicly available count matrices, whereas those for the fourth were obtained from the original publications. Using RNA-seq evidence, DEGORA recovered 93% of interferon, 59% of endoplasmic reticulum stress, 73% of heat-shock, and 85% of hypoxia markers among the top 100 ranked genes. In three confirmatory datasets, DEGORA showed no consistent ranking advantage over alternative methods applied to the same tables. The same workflow organized published Alzheimer's disease cohort evidence without recomputing differential expression. Across ten evaluated datasets, performance varied with how the input tables were generated. Overall, DEGORA organizes differential expression evidence at the study level and keeps every ranked gene linked to the publications, assays, and reported statistics behind it.

RevDate: 2026-11-14

Zamani A, Jenkins L, Rodger J, et al (2026)

A hypothesis framework linking the menopausal transition, sleep and brain waste clearance: Insights from experimental models.

Frontiers in neuroendocrinology pii:S0091-3022(26)00070-1 [Epub ahead of print].

The menopausal transition is increasingly recognized as a neuroendocrine transition with implications for brain health, sleep, cognition and vulnerability to neurodegenerative disease. Fluctuating and declining ovarian hormones coincide with sleep disruption, vasomotor symptoms, cognitive complaints, neuroinflammation and altered blood-brain barrier integrity. Current preclinical models each capture selected components of the menopause transition and provide essential mechanistic insights into the effect of ovarian hormone loss on the brain. Across these models, endocrine change is associated with impairments in hippocampal and prefrontal-dependent cognition, altered sleep-wake regulation, vascular dysfunction, glial activation, disrupted synaptic and mitochondrial homeostasis and exacerbation of Alzheimer's and Parkinson's disease-like pathology. An emerging but understudied mechanism linking menopause, sleep and neurodegeneration is the glymphatic system, a sleep-dependent brain waste clearance pathway. This review synthesises current evidence to highlight how menopause-related sleep disruption, vascular dysfunction, neuroinflammation and potential alterations in brain-waste clearance may converge to shape cognitive ageing and neurodegenerative disease risk.

RevDate: 2026-11-14

Zou Y, Wang Y, Ma X, et al (2026)

Corrigendum to "CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis" [Ageing Res. Rev. 101 (2024) 102485].

RevDate: 2026-11-15
CmpDate: 2026-11-15

Souza R, Stepanchuk AA, Brandt PJ, et al (2026)

End-to-end deep learning for identifying Alzheimer's disease signatures in spectral fluorescence imaging of normal-appearing brain regions in 5xFAD mice.

Journal of medical imaging (Bellingham, Wash.), 13(6):064001.

PURPOSE: Alzheimer's disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid- β and tau aggregates in the brain. Current diagnostic approaches primarily detect mature plaques, but growing evidence suggests that pre-fibrillar aggregates are present earlier in normal-appearing tissue and may provide a valuable window for intervention. We propose the first proof-of-concept end-to-end deep learning (DL) model to identify AD signatures directly from normal-appearing tissue (i.e., background parenchyma) of raw spectral fluorescence data.

APPROACH: To develop and evaluate our DL model, we used one million signals extracted from spectral fluorescence images of brain cortex sections collected from wild-type and 5xFAD mice (a transgenic strain carrying five familial human AD mutations).

RESULTS: Our results demonstrate that AD-related signatures can indeed be detected in normal-appearing brain cortex regions. Experiments revealed that model performance depends on input dimensions, training set size, and the preprocessing kernel size. The optimal configuration used 1000 × 32 input, 9000 training samples, and a 3 × 3 kernel, achieving ≥ 95 % accuracy, sensitivity, specificity, F 1 -score, and area under the receiver operating characteristic curve. Importantly, no mice were misclassified, and saliency analysis indicated that a broad range of spectral fluorescence wavelengths contributed to the model's decisions.

CONCLUSIONS: These findings highlight the potential of DL-based analysis of spectral fluorescence data to enable earlier detection of AD-related changes, supporting a shift toward a more proactive strategy for biomarker discovery.

RevDate: 2026-11-15
CmpDate: 2026-11-15

de Andrade EJN, Salles GR, de Andrade Giraldi L, et al (2026)

From neurotoxicity to neuroprotection: photobiomodulation against the effects of the SARS-CoV-2 spike protein in a 2D neurodegenerative model using differentiated SH-SY5Y cells.

In vitro models, 5(4):577-589.

Alzheimer's disease (AD) is a major cause of dementia and remains a significant global health challenge, with no curative treatments currently available. The COVID-19 pandemic has raised concerns regarding neurological complications associated with SARS-CoV-2, particularly the role of the Spike protein in neurotoxicity. This study investigated the neurotoxic effects of recombinant Spike protein in a two-dimensional (2D) in vitro model of oxidative-induced neuronal injury, as well as the potential protective role of photobiomodulation (PBM, 3 J/cm[2]) using a red LED (660 nm). Differentiated SH-SY5Y cells were exposed to Spike protein (0.5 µg/mL) and H2O2 (200 µM), individually or in combination, with or without PBM. Cell viability was assessed using the Alamar Blue assay, while immunofluorescence analysis was performed to evaluate nuclear morphology, mitochondrial integrity, cytoskeletal organization, and focal adhesion dynamics. Flow cytometry (Annexin V/PI and CellROX) was used to quantify apoptosis, cell death, and intracellular reactive oxygen species (ROS). Results demonstrated that the Spike protein induced mitochondrial fragmentation, cytoskeletal disorganization, and increased oxidative stress, leading to enhanced apoptotic susceptibility. These effects were exacerbated under oxidative conditions, indicating a synergistic interaction. PBM attenuated these alterations by reducing ROS levels, apoptosis, and structural damage, while preserving cellular integrity. Overall, these findings indicate that the Spike protein acts as a modulator of redox imbalance, contributing to neuronal dysfunction in an in vitro oxidative stress model. PBM emerges as a promising non-pharmacological strategy capable of mitigating these effects through modulation of mitochondrial function and cellular redox homeostasis.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Kuchenbecker LA, Piura YD, Tipton PW, et al (2026)

Plasma biomarker signatures in patients with rapidly progressive dementia.

Alzheimer's & dementia (Amsterdam, Netherlands), 18(4):e70541.

INTRODUCTION: Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions.

METHODS: Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging.

RESULTS: Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p-tau)217 and p-tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment-non-responsive causes of RPD.

DISCUSSION: Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Ejaz MM, Iftikhar H, Al-Namshah KS, et al (2026)

Substituent effects on electronic properties and predicted acetylcholinesterase binding potential of donepezil analogues: a DFT, molecular docking, and ADMET study with dynamics assessment of the lead candidate.

In silico pharmacology, 14(3):284.

UNLABELLED: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common cause of dementia in older people. Donepezil is an acetylcholinesterase inhibitor used for symptomatic management of AD. Due to its clinically established AChE inhibition; it was used as a reference. In this study, a series of donepezil derivatives (MH-1 to MH-5) were designed by introducing a para substituent (NH2, NO2, Cl, OH or OCH3) on the benzyl moiety and systematically investigated along with the R using density functional theory, time-dependent DFT, molecular docking, and in silico pharmacokinetics analysis. The geometry optimization and electronic structure calculations were performed using the B3LYP/6-311G (d, p) level. Frontier molecular orbital analysis indicated reduced energy gaps in MH-1 and MH-2. The in silico molecular docking analysis of all derivatives and the R was performed against the acetylcholinesterase receptor (PDB ID 4EY7), where MH-1, MH-2, and MH-4 showed Vina scores equal to the R (- 12.2 kcal/mol). MH-4 was selected for a single 300 ns molecular dynamics simulation (unlike MH-1 and MH-2, it had no predicted mutagenicity alert). The protein backbone RMSD stayed mostly between 0.15 and 0.22 nm, and the ligand stayed in contact with the protein while changing its conformation and orientation. MM-GBSA enthalpy was stable across sampling densities (ΔH ≈ -24.6 kcal/mol), whereas the Interaction Entropy-corrected binding free energy varied with the number of frames analysed (ΔG = - 9.76 to - 15.71 kcal/mol, standard error ≈ 3.7-4.0 kcal/mol). Moreover, ADMETlab 3.0 predicted high intestinal absorption. ProTox 3.0 predicted several toxicity alerts for all compounds, including immunotoxicity and respiratory toxicity; MH-1 and MH-2 were also flagged for mutagenicity. In summary, MH-4 is proposed as a candidate for experimental evaluation. All results are computational predictions and require experimental validation.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00786-2.

RevDate: 2026-11-15
CmpDate: 2026-11-15

de Andrade Giraldi L, Rodrigues Salles G, Nogueira de Andrade EJ, et al (2026)

Neurotherapeutic potential of photobiomodulation in a 3D Model of Alzheimer's disease induced by oxidative stress.

In vitro models, 5(4):549-556.

PURPOSE: Alzheimer's disease (AD) is a progressive neurodegenerative condition that, despite its high global incidence, still lacks effective treatments capable of altering its course. Therefore, this study aimed to investigate the neuroprotective effects of photobiomodulation (PBM, 660 nm) in a three-dimensional (3D) neuronal model of AD induced by oxidative stress. We sought to determine whether PBM could attenuate cellular damage, reduce oxidative imbalance, and preserve neuronal morphology under AD-like conditions.

METHODS: A previously validated 3D neuronal model of AD, based on differentiated SH-SY5Y spheroids stressed with H2O2 (200 µM, 1 h), was used. Spheroids were assigned to four experimental groups (Control, PBM, H2O2, H2O2+PBM). PBM was performed by 660 nm LED irradiation (3 J/cm²). Cell viability, intracellular reactive oxygen species (ROS) levels, and neuronal morphology were assessed.

RESULTS: PBM increased cell viability in both control and H2O2-exposed spheroids, with partial recovery of metabolic activity following oxidative injury. Intracellular ROS levels were significantly reduced by PBM, indicating attenuation of the oxidative imbalance. Morphological evaluation showed partial preservation of neuronal architecture, with PBM reducing nuclear and structural disruptions characteristic of oxidative stress.

CONCLUSION: PBM attenuated oxidative damage in a 3D model of AD, by increasing cell viability, reducing intracellular ROS, and partially preserving neuronal morphology. These findings support PBM as a promising adjuvant therapeutic approach for neurodegenerative conditions and reinforce the relevance of 3D neuronal spheroids as a platform for in vitro AD research.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Siervo M, Brain J, Beasley S, et al (2026)

Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control.

EClinicalMedicine, 101:104310.

BACKGROUND: Smoking has been identified as a modifiable dementia risk factor by three Lancet Commissions, yet dementia remains absent from most tobacco control strategies. The magnitude of the association across dementia subtypes, smoking categories, and population characteristics has not been comprehensively synthesised since 2015.

METHODS: PubMed, Embase, CENTRAL, and PsycINFO were searched from January 2013 to 31 August 2026, updating the 2015 review, which contributed 34 studies. Random-effects meta-analyses (Restricted Maximum Likelihood (REML) with Hartung-Knapp-Sidik-Jonkman adjustment) estimated pooled relative risks (RRs) with 95% confidence intervals (CIs). Subgroup analyses with tests for interaction and meta-regression examined effect modification by baseline age, ethnicity, follow-up duration, and adjustment for sex, education and Apolipoprotein E ε4 (APOE ε4) genotype. Risk of bias was assessed using Risk Of Bias In Non-randomized Studies of Exposures (ROBINS-E). Heterogeneity was assessed using Cochran's Q, I[2] and τ[2] and publication bias using funnel plots and Egger's test. Dose-response analysis of smoking and dementia risk was performed. Smoking population attributable fractions (PAF, unweighted and communality-weighted) for the risk of dementia were calculated. This study is registered with PROSPERO, CRD42025644539.

FINDINGS: Sixty-one cohort studies (approximately 2.8 million participants) were included. Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23-1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08-1.80]; k = 15), and vascular dementia (1.52 [1.20-1.93]; k = 9). Former smoking was not associated with any outcome, and former smokers had a lower risk of all-cause dementia than current smokers (RR 0.81 [0.75-0.88]). I[2] ranged from 0% to 80%. Egger's test suggested small-study effects only for current smoking and all-cause dementia (P = 0.09). The communality-weighted PAF for smoking and dementia was 2.2% (95% CI 1.7-2.8). Dementia risk increased with smoking intensity as the pooled RR was 1.16 (95% CI 1.09-1.23) at 10 cigarettes per day and rose to 1.34 (95% CI 1.18-1.51) at 20 cigarettes per day.

INTERPRETATION: Current smoking is consistently associated with higher risk of all dementia outcomes and increases with smoking intensity. Estimates refer to clinically diagnosed dementia syndromes [Diagnostic and Statistical Manual of Mental Disorders/International Classification of Diseases (DSM/ICD)] and not to biologically defined disease. Although causality cannot be established from observational data, these findings support considering dementia and brain health outcomes in national tobacco control strategies and associated campaigns. Future work using objectively verified smoking histories is needed to clarify how age at cessation and time since quitting influence dementia risk and whether these effects interact with total years of active smoking.

FUNDING: None.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Parsons S, Williamson S, SAL Corrêa (2026)

Elevated Phosphorylated Tau and Amyloid-Beta 42 in Sleep Apnoea: Evidence From a Systematic Review and Meta-Analysis.

BioMed research international, 2026(1):.

BACKGROUND: Alzheimer's disease (AD) biomarkers were detected in the cerebrospinal fluid, plasma and brain of obstructive sleep apnoea hypopnoea syndrome (OSAHS) sufferers. The mechanism mediating these changes remains disputed. This study aims to investigate the relationship between chronic intermittent hypoxia caused by OSAHS and AD blood biomarker levels, allowing a better understanding and consideration of the systemic impact of OSAHS on AD development.

METHODS: We searched PubMed, Scopus and Web of Science databases and conducted the research according the PRISMA 2020 guidelines. Studies were included if they reported hypoxic parameters in an OASHS group and a control group and analyses of blood biomarker levels including amyloid-beta and tau. The Newcastle-Ottawa Scale was used to assess study quality.

RESULTS: Eight studies including 435 OSAHS patients and 281 controls were assessed. Pooled analysis showed elevated Aβ42 (SMD = 0.27, 95%(CI) = 0.03 to 0.51, I[2] = 56%, p = 0.03), T-tau (SMD = 0.60, 95%(CI) = 0.26 to 0.94, I[2] = 63%, p = 0.0006) and p-tau181 (SMD = 0.41, 95%(CI) = 0.03 to 0.80, effect size = 2.12, I[2] = 51%, p = 0.03) in the OSAHS group compared with controls, though no difference in Aβ40 (SMD = 0.33, 95%(CI) = -0.27 to 0.94, effect size = 1.09, I[2] = 77%, p = 0.28) levels was observed. Reduced mean oxygen saturation is associated with elevated T-tau (SMD = -0.36, 95%(CI) = -0.62 to - 0.10, I[2] = 0%, p = 0.007) and p-tau181 (SMD = -0.61, 95%(CI) = -0.96 to - 0.27, I[2] = 0%, p = 0.0004) but not with Aβ42 (SMD = -0.19, 95%(CI) = -0.70 to 0.32, I[2] = 76%, p = 0.46). Elevated oxygen desaturation index was associated with increased Aβ42 (SMD = -0.37, 95%(CI) = -0.56 to - 0.18, I[2] = 49%, p = 0.0001) and T-tau (SMD = -0.54, 95%(CI) = -0.90 to - 0.17, I[2] = 58%, p = 0.004).

CONCLUSIONS: Findings show that chronic intermittent hypoxia is associated with increased blood Aβ42 levels,, but not Aβ40, in the OSAHS group. This may suggest that hypoxia contributes to processes regulating the production and degradation of neurotoxic amyloid-beta peptides. Further experimental investigation is required to determine whether treating OSAHS and restoring optimal oxygen saturation conditions in the brain affects blood Aβ42 levels and whether OSAHS is a modifiable disorder that may increase the risk of developing AD.

RevDate: 2026-11-15

Chen Z, Pang Y, Ju Y, et al (2026)

Dietary Sugar Intake and Risk of Cognitive Disorders: A Systematic Review and Meta-Analysis.

Nutrition reviews pii:9063609 [Epub ahead of print].

CONTEXT: Although prior studies have linked excessive dietary sugar intake to adverse cognitive outcomes, the findings of individual studies remain inconsistent, and there is a lack of synthesis.

OBJECTIVE: The objective of this study was to comprehensively examine the association between dietary sugar intake and risk of cognitive disorders.

DATA SOURCES: The Cochrane, Embase, PubMed, ScienceDirect, and Web of Science databases were searched from inception to December 2025.

DATA EXTRACTION: Prospective cohort, nested case-control or case-cohort studies evaluating the association of dietary total sugar or its subtypes with the risk of cognitive disorders, including cognitive impairment and dementia (including Alzheimer's disease), in adults were reviewed. Details of the studies and main outcomes were extracted independently by 2 reviewers.

DATA ANALYSIS: Among 2171 records screened, 10 prospective cohort studies comprising 12 cohorts and 257 761 participants were included. The number of cohorts and participants for each exposure was as follows: total sugar: 5 (N = 200 812); sugar-sweetened beverages: 9 (N = 214 084); fruit juice: 2 (N = 194 847); fructose: 4 (N = 197 082); sucrose: 3 (N = 194 928); lactose: 3 (N = 194 928); maltose: 3 (N = 194 928); glucose: 3 (N = 194 928). Meta-analysis indicated that individuals with the highest total sugar intake were at a higher risk of cognitive disorders compared with those with the lowest intake (hazard ratio = 1.23, 95% CI = 1.10-1.38, low certainty). No significant associations were observed for any specific sugar subtypes examined, with certainty of evidence ranging from low to very low.

CONCLUSIONS: The present review suggests that higher total sugar intake may be associated with an increased risk of cognitive disorders. In contrast, the current evidence does not support a clear association between specific sugar subtypes and cognitive disorders. Future studies should prioritize clarifying the dose-response relationship between total sugar intake and cognitive disorders.

PROSPERO registration No. CRD42025640308.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Zhang N, Liu M, J Gu (2026)

Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment.

Research square.

BACKGROUND: Mild cognitive impairment (MCI) is often conceptualized as an intermediate stage between normal cognition and dementia. However, emerging evidence suggests that cognitive status may change bidirectionally, with individuals experiencing reversion to normal cognition, persistent impairment, or progression to dementia. Previous studies have focused on single transitions or clinical samples frequently. This study aimed to characterize dynamic transitions among normal cognition, MCI, and dementia following incident MCI using longitudinal population-based data.

METHODS: We conducted a retrospective cohort study using data from the Health and Retirement Study (HRS) from 1992 to 2022. Cognitive status was classified at each biennial assessment using the Langa-Weir cognitive classification based on the modified TICS and proxy assessments. Incident MCI was defined as a transition from previously observed normal cognition to MCI. Participants were followed for up to five subsequent HRS waves (approximately 10 years). Descriptive statistics were used to describe changes of cognitive status between waves. A continuous-time multistate Markov model wase used to estimate transition intensities and transition probabilities among normal cognition, MCI, and dementia, including both progression and reversion.

RESULTS: Among 10,489 participants with incident MCI, the mean age at the incident MCI wave was 70.6 years (SD = 11.53), and 56.6% were female. Two years after incident MCI, 62.3% of observed participants were classified as having normal cognition, 31.2% remained in MCI, and 6.5% were classified as having dementia. At 4, 6, 8, and 10 years after incident MCI, the proportion classified as normal cognition declined while the proportion of participants with dementia increased. The multistate model demonstrated substantial bidirectional movement among cognitive states. The estimated transition intensity from MCI to normal cognition was 0.453 (95% CI 0.443-0.463), compared with 0.126 (95% CI 0.121-0.131) for MCI to dementia. Transitions also occurred from normal cognition to MCI (0.265; 95% CI 0.257-0.273) and dementia (0.037; 95% CI 0.035-0.041), as well as from dementia to MCI (0.226; 95% CI 0.209-0.245) and normal cognition (0.064; 95% CI 0.055-0.074).

CONCLUSIONS: Cognitive trajectories following incident MCI were heterogeneous and dynamic, involving reversion, persistence, progression, and recurrent transitions among cognitive states. These findings support a multistate conceptualization of cognitive aging rather than a predominantly unidirectional model of progression toward dementia. Although reversion in cognitive classification should not be interpreted as definitive biological recovery, its frequent occurrence highlights the importance of repeated longitudinal assessment and further investigation of factors associated with cognitive resilience and dementia risk.

RevDate: 2026-11-13

Ardjmand A, Khoshnam SE, Zarjani AK, et al (2026)

Recent advances on the role of microRNAs in Alzheimer's Disease: Unraveling Mechanisms and Therapeutic Potential.

Brain research bulletin pii:S0361-9230(26)00496-X [Epub ahead of print].

MicroRNAs (miRNAs) are now recognized as key regulators of the pathogenesis of Alzheimer's disease (AD) and offer promising opportunities for early detection and treatment. Some miRNAs are responsible for controlling and modulating neuroinflammatory responses, while others directly affect the process of amyloid beta (Aβ) production. Their relative stability in biological fluids supports their potential use in diagnostic panels; however, their diagnostic performance requires further validation before clinical application. From a therapeutic perspective, miRNA antagonists and mimetics have been shown in preclinical studies to reduce amyloid pathology, ameliorate cognitive impairment, and stimulate neurogenesis in animal models of AD. In this review article, we summarize the evidence on the diverse and multifaceted functions of miRNAs in key aspects of AD pathology, including Aβ synthesis via BACE1 and APP regulation, tau aggregation and phosphorylation, APOE4 signaling cascades, oxidative stress, neuroinflammation, and synaptic plasticity. By linking mechanistic understanding of miRNAs with potential translational applications, miRNA-based strategies may offer promising opportunities for improving the early diagnosis and treatment of AD. However, further preclinical validation and rigorous clinical studies are needed to establish their safety, efficacy, and clinical utility.

RevDate: 2026-11-13

Dumurgier J (2026)

Metformin and the ageing brain: what biomarkers can and cannot tell us.

RevDate: 2026-11-13

Abanto J, Dwivedi AK, Imbimbo C, et al (2026)

Metformin use is associated with lower plasma NfL, higher CSF Aβ42 and better cognitive performance.

Journal of neurology, neurosurgery, and psychiatry pii:jnnp-2026-339219 [Epub ahead of print].

RevDate: 2026-11-14

Kaplan C, Perepezko K, Pontone GM, et al (2026)

Transdiagnostic Mechanisms Underlying Nonaffective Psychosis: A Role for Hippocampal Networks?.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry [Epub ahead of print].

Psychosis is a functionally disruptive syndrome that results in an impaired sense of reality. People with psychosis have higher rates of mortality and institutionalization compared to the general population, necessitating evaluation and treatment in both neurologic and psychiatric practice. Effective treatments for psychosis require an understanding of the underlying neurobiological mechanisms that may be driving specific psychosis symptoms; however, previous efforts to assess these mechanisms have been challenging due to the heterogenous course and presentation. This review aims to provide a synthesis of what is currently known about psychosis and psychotic symptoms in primary and secondary nonaffective disorders, focusing on the most prevalent conditions in which these symptoms occur: schizophrenia, Parkinson's disease, and Alzheimer's disease. We review the phenomenology, prevalence, and natural history of psychosis in these disorders and highlight features and mechanisms thought to underlie specific psychosis symptoms across these disorders. The reviewed evidence reveals that psychosis is diagnosed differently depending on the disease context; however, the onset of well-formed psychotic symptoms is consistently preceded by a prodromal period in which attenuated symptoms present and insight is retained. In addition, symptoms are strongly linked to cognitive impairment, particularly short-term memory impairment, further supporting the notion of transdiagnostic mechanisms underlying psychosis. While this review provides an overview of key similarities and differences in psychosis symptoms across schizophrenia, Parkinson's disease, and Alzheimer's disease, more research is needed to explore several gaps identified in this review.

RevDate: 2026-11-13
CmpDate: 2026-11-13

Ghisays V, Denkinger MN, Singh A, et al (2026)

Prognostic value of plasma brain-derived phosphorylated Tau.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Plasma brain-derived phosphorylated Tau217 (BD-pTau217) may provide a more Alzheimer's disease (AD) -specific plasma tau measure than total pTau217, but its prognostic value is unclear.

METHODS: We compared baseline plasma NULISAseq biomarkers for amyloid positron emission tomography (PET) progression (positivity: Centiloid ≥ 24.1; n = 175) and clinical progression to mild cognitive impairment or AD dementia (n = 508) in cognitively unimpaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants using Cox models and time-dependent areas under the curve (tdAUCs).

RESULTS: Over a median clinical follow-up of 6 years (interquartile range [IQR], 3.0-7.3), BD-pTau217 and total pTau217 had similar discrimination (full-follow-up AUC = 0.66 each; high-versus-low hazard ratios [HRs]; 95% confidence interval [CIs]: 2.8 [1.89-4.06] and 2.9 [1.96-4.35], respectively). Among initially amyloid-negative participants, BD-pTau217 better predicted progression to amyloid PET positivity at 2.5 years (tdAUC 0.82 vs. 0.69; HR = 10.54 [95% CI 2.3-48.1], p = 0.00015) and 4 years (tdAUC 0.77 vs. 0.64; HR = 7.03 [95% CI 1.9-25.6], p = 0.00055) compared to total pTau217.

CONCLUSION: BD-pTau217 better predicted near-term progression to amyloid PET positivity than total pTau217, but showed no advantage for clinical progression, supporting its potential value as an early marker of AD pathological change.

RevDate: 2026-11-13
CmpDate: 2026-11-13

Oveisgharan S, Yu L, Taylor ZW, et al (2026)

Tau ubiquitination and phosphorylation in relation to Alzheimer's disease in older adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: It is unknown how soluble tau protein turns into insoluble tau tangle. We tested whether tau ubiquitination and phosphorylation were associated with tau tangles.

METHODS: Data were from participants in the Rush Memory and Aging Project. Proteomic analysis quantified tau protein and its ubiquitination and phosphorylation levels. Pathological examination collected Alzheimer's disease (AD) pathological indices (amyloid-β [Aβ] load and tau tangles), and neuropsychological tests' scores were used for estimating cognitive decline.

RESULTS: Tau ubiquitination positions were correlated and related to more tau tangles while tau phosphorylation at only some positions was related to tau tangles. Tau ubiquitination statistically mediated the association of tau phosphorylation with tau tangles, and tau phosphorylation and ubiquitination statistically mediated 56.5% of Aβ-tau tangle association, suggesting phosphorylation and ubiquitination of tau contributing to tau tangle formation.

CONCLUSION: Targeting pathways underlying tau ubiquitination may partially slow down the accumulation of Aβ-induced tau tangle accumulation.

RevDate: 2026-11-13
CmpDate: 2026-11-13

Leenings R, Winter NR, Ernsting J, et al (2026)

Contextualizing biological heterogeneity in brain structural normativity assessments across the aging continuum with the nearest neighbor normativity framework.

Communications medicine, 6(1):.

BACKGROUND: Despite established consensus about the individuality of brain physiology and structural changes, current neuroimaging biomarker paradigms heavily rely on population averages. Here, we define normativity not as a single reference point but as a landscape of permissible configurations arising from diverse physiological manifestations.

METHODS: We introduce the Nearest Neighbor Normativity (N[3]) framework, designed to parse the natural heterogeneity in brain structural measurements into a diversity-aware biomarker of brain structural decline. Through repeated comparisons within different demographic subgroups, N[3] contextualizes an individual's measurements from several viewpoints along the aging continuum. Relying on local density estimation, it accommodates multiple, shared normative configurations within and across age groups. We use T1-weighted MRI data from 29,883 individuals for training and 7,013 individuals for validation, and benchmark our framework against Brain Age models and Normative Modeling. We evaluate each biomarker's ability to detect neurodegenerative diseases, using them as representative models of atypical brain structural decline.

RESULTS: In group-level analyses, the N[3] biomarker shows the largest effect sizes in the detection of Mild Cognitive Impairment, Alzheimer's Disease, and Frontotemporal Dementia. Similarly, the N[3] biomarker achieves the highest predictive performance in the classification of neurodegenerative diseases on a single subject level. Notably, the N[3] estimates remain stable across age and robust to compositional changes in the reference sample. Finally, correlation analyses indicate that it captures distinct and complementary aspects of brain structural variation compared to existing approaches.

CONCLUSIONS: Our findings underscore that rethinking normativity assessments to explicitly accommodate natural inter-individual variability can advance our collective efforts toward truly personalized patient care.

RevDate: 2026-11-13
CmpDate: 2026-11-13

Jester HM, Wang X, Li T, et al (2026)

Suppression of neuronal eEF2K alleviates cognitive deficits and apathy-like behavior in APP/PS1 AD model mice.

Translational psychiatry, 16(1):.

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by synaptic failure, cognitive impairment and neuropsychiatric symptoms (NPS). Apathy is the most common NPS seen in AD patients, and its underlying mechanisms remain unknown. Here, we investigated the roles of neuronal eukaryotic elongation factor 2 (eEF2) phosphorylation (by its kinase eEF2K) in AD-associated cognitive deficits and NPS. We performed a series of experiments using a multidisciplinary approach including genetics, behavioral assays, synaptic electrophysiology, and unbiased proteomics. The results demonstrated that neuron-specific inhibition of eEF2K and eEF2 phosphorylation can alleviate cognitive deficits, synaptic plasticity impairments, and apathy-like behavior in aged APP/PS1 AD model mice. Our findings indicate the therapeutic potential of targeting the eEF2K signaling in the treatment of dementia and NPS in AD and related dementias (ADRDs).

RevDate: 2026-11-13
CmpDate: 2026-11-13

Kennedy WM, Troyano-Rodriguez E, Higgs MH, et al (2026)

Tau conveys intrinsic hyperactivity of VTA dopamine neurons but an inability to sustain burst firing.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Ventral tegmental area (VTA) dopamine is implicated in neuropsychiatric symptoms in Alzheimer's disease (AD). Mouse AD models show dopamine neuron hyperexcitability, but also decreased dopamine release and disrupted reward learning. Specific roles for amyloid and tau have not been determined.

METHODS: We investigated the triggers of disrupted dopamine neuron firing in mouse AD models: 3xTg-AD (amyloid+tau), APP[NL] [-G-F] (amyloid only), and a viral model expressing pathogenic human tau (p-tau).

RESULTS: 3xTg-AD dopamine neurons showed less bursting in vivo, yet faster non-burst spiking. In ex vivo slices, these neurons showed impaired ability to sustain firing during depolarization, which we mimicked with depolarizing current in wild-type neurons. Inducing p-tau expression similarly caused firing aberrations, effects not recapitulated in APP[NL-G-F] neurons.

DISCUSSION: P-tau induces hyperexcitability within individual dopamine neurons, but this likely reduces transmission in vivo through impaired bursting. Further studies investigating dopamine release in vivo may elucidate timepoints for early AD intervention.

RevDate: 2026-11-14
CmpDate: 2026-11-13

Lund AN, Thompson RC, Wang YC, et al (2026)

Updates to the reference genome alter the detection and direction of genes differentially expressed in Alzheimer's disease.

Genome biology, 27(1):.

BACKGROUND: Alzheimer's Disease gene expression studies often rely on the reproducibility of known disease associations to build confidence in novel discoveries. This approach assumes that true biological variation associated with Alzheimer's Disease is robust to a range of technical and biological confounders that likely differ across experiments. Here, we systematically assess the impact of an important yet frequently overlooked technical confounder in Alzheimer's Disease differential expression analysis: changes in gene quantification resulting from ongoing updates to the human genome reference and transcriptome annotations.

RESULTS: To investigate this, gene expression in a large brain transcriptomic dataset from Alzheimer's Disease patients and controls (ROSMAP) was quantified using five transcriptome annotations mapped across a broad range of human genome references, from NCBI36 to CHM13v2.0. Although nearly all genes exhibit significant differences in expression between reference pairs (i.e., were differentially quantified), genome-wide Alzheimer's Disease differential expression signatures remain highly concordant across references. Notably, while a core set of significantly differentially expressed Alzheimer's Disease genes is largely conserved across references, reference-specific Alzheimer's Disease-associated genes are enriched for pathways known to be involved in the disease. Genes whose direction of association with Alzheimer's Disease significantly differs across references are also identified, highlighting the potential influence of reference choice on Alzheimer's Disease-relevant genes and pathways. All results were replicated in an independent transcriptomics dataset (MSBB) derived from the same brain region.

CONCLUSIONS: These findings demonstrate that reference genome choice impacts the identification and interpretation of specific Alzheimer's Disease-associated genes, despite overall reproducibility of genome-wide differential expression signatures, underscoring the critical importance of reference selection in Alzheimer's Disease transcriptomic studies.

RevDate: 2026-11-13
CmpDate: 2026-11-13

Guterman EL, Dulaney SA, Sawyer RJ, et al (2026)

Caregiver well-being after multisite implementation of the Care Ecosystem.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Collaborative dementia care models improve outcomes in prior randomized trials, but whether these benefits are maintained when implemented at scale remains uncertain. We evaluated the association of community-based implementation of the Care Ecosystem with caregiver well-being.

METHODS: We conducted a pragmatic multisite study of 1186 persons living with dementia (PLWD) and caregiver dyads enrolled across six US health systems between January 17, 2023 and July 12, 2024. Participants received the Care Ecosystem, a navigator-led dementia care program delivered remotely through multidisciplinary teams. The primary outcome was caregiver depression (9-item Patient Health Questionnaire [PHQ-9]). Secondary outcomes included anxiety, caregiver distress related to neuropsychiatric symptoms of the PLWD, caregiver strain, and self-efficacy. Outcomes were assessed at baseline, 6 months, and 12 months using linear mixed-effects models.

RESULTS: Among 1186 dyads, caregivers had a median age of 65.4 years (interquartile range: 54.8-74.9) and 71.9% were women. Caregiver depression scores were lower at 12 months (mean change in PHQ-9 score, -0.48; 95% confidence interval [CI], -0.71 to -0.25). Improvements were also observed in anxiety (-0.23; 95% CI, -0.33 to -0.13), distress related to neuropsychiatric symptoms (-0.82; 95% CI, -1.32 to -0.32), caregiver strain (-0.45; 95% CI, -0.80 to -0.11), and self-efficacy (2.01; 95% CI, 1.82 to 2.20). Larger improvements were observed among caregivers of persons with moderate-to-severe dementia and in several caregiver groups, including adult children and those who identified as Black and Hispanic.

DISCUSSION: These findings suggest that implementation of collaborative dementia care in routine practice may be associated with improvements in caregiver well-being.

RevDate: 2026-11-13

Horie K, Koppisetti RK, VandeVrede L, et al (2026)

Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology.

JAMA pii:2856780 [Epub ahead of print].

IMPORTANCE: Neurodegenerative diseases with abnormal tau protein aggregation in the brain (ie, tauopathies) can be classified by the tau isoform that accumulates: 3-repeat (3R), 4-repeat (4R), or mixed 3R/4R tauopathies, which include chronic traumatic encephalopathy (CTE), some forms of frontotemporal lobar degeneration, and Alzheimer disease (AD). The endogenously cleaved form of tau microtubule binding region containing the residue 243 (eMTBR-tau243) can be detected in cerebrospinal fluid (CSF) and blood and has been associated with AD tau pathology, but its specificity and biological interpretation in non-AD tauopathies remains unclear.

OBJECTIVE: To evaluate biofluid eMTBR-tau243 in a range of tauopathies.

This case-control study included 4 biorepositories based in the US that contributed CSF and plasma samples from participants with and without tauopathies, many of whom had antemortem biofluid samples paired with autopsy or genetically defined neuropathology. Samples were analyzed between August 2023 and December 2025. Data analysis occurred from August 2024 to July 2026.

EXPOSURE: CSF and plasma eMTBR-tau243 concentrations measured using a mass spectrometry-based assay.

MAIN OUTCOMES AND MEASURES: Outcomes included mixed 3R/4R tauopathy (eg, AD and CTE) based on autopsy, frontotemporal lobar degeneration with MAPT variants (FTLD-MAPT), and CTE stage. Differences in biomarker levels between groups were evaluated using analysis of variance or analysis of covariance, and area under the receiver operating characteristic curve (AUC) was calculated to evaluate the discriminative performance of fluid eMTBR-tau243.

RESULTS: Among the 229 participants (196 with CSF samples and 55 with plasma samples [22 with both]), mean (SD) age at fluid sample collection was 63 (13) years and 108 (47%) were female. Median (IQR) CSF eMTBR-tau243 was increased in 10 patients with AD (0.459 [0.246-0.801] fmol/mL) compared with 29 cognitively unimpaired controls (0.002 [0.001-0.005] fmol/mL) (adjusted P < .001), but other autopsy-confirmed non-AD tauopathies (which included 52 individuals with conditions including progressive supranuclear palsy and corticobasal degeneration) did not demonstrate an increase (0.015 [0.008, 0.039] fmol/mL). Six symptomatic FTLD-MAPT variant carriers with mixed 3R/4R tauopathy (R406W, V337M, and G389R) had increased median (IQR) CSF eMTBR-tau243 (0.140 [0.055-0.174] fmol/mL) compared with 15 4R tauopathy variant carriers including N279K and P301L (0.004 [0.001-0.044] fmol/mL) (P = .001). Median (IQR) plasma eMTBR-tau243 was increased in 11 patients with CTE (1.93 [0.42-3.68] fmol/L) compared with 20 cognitively unimpaired controls (0.29 [0.05-0.62] fmol/L) (adjusted P = .007), but did not increase as high as among 14 patients with AD (11.25 [2.29-19.38] fmol/L). Plasma eMTBR-tau243 distinguished CTE stage III and IV from controls (AUC, 0.97; 95% CI, 0.92-1.00), but not CTE stage I from controls (AUC, 0.64; 95% CI, 0.32-0.97).

CONCLUSIONS AND RELEVANCE: This study found that plasma and CSF eMTBR-tau243 were increased in mixed 3R/4R tauopathies including AD, high-stage CTE, and a subset of genetic FTLD-MAPT, compared with cognitively unimpaired controls. Further validation in larger cohorts is needed to determine the clinical utility of eMTBR-tau243 as a potential diagnostic biomarker for CTE and other tauopathies beyond AD.

RevDate: 2026-11-14

Cheng F, Fransson LÅ, K Mani (2026)

Apolipoprotein E4 (ApoE4) causes disruption of glypican-1 recycling and processing in ApoE4/4 fibroblasts and induced neurons.

Glycobiology pii:9049835 [Epub ahead of print].

The apolipoprotein E4 (ApoE4) isoform confers increased risk of developing Alzheimer's disease. ApoE2 and ApoE3 can be S-nitrosylated (Cys-SNO), but not ApoE4. The recycling heparan sulfate (HS) proteoglycan glypican-1 (GPC1) can also carry SNO and release HS by a Cu/NO dependent cleavage. ApoE3/3 and ApoE4/4 fibroblasts and the respective induced neurons (-iN) were exposed to inhibitors of NO-synthases (NOS), to NO donor or ascorbate and examined by immunofluorescence microscopy. Exposure to NO donor increased co-localization between ApoE3-SNO and GPC1 in ApoE3/3 fibroblasts. Co-localization between ApoE3 and GPC1 diminished when cNOS/NOS3 was inhibited in ApoE3/3 fibroblasts. Exposure to NO donor or ascorbate indicated almost fully utilized capacity to release HS from GPC1. When nNOS/NOS1 and iNOS/NOS2 were inhibited in ApoE3/3-iN, release of HS decreased, and exposure to ascorbate again showed that the capacity to release HS was almost fully utilized. In ApoE4/4 fibroblasts endosome transport was retarded and HS and GPC1-SNO accumulated in late endosomes. Inhibition of cNOS/NOS3 in ApoE4/4 fibroblasts had no effect on HS release but inhibition of iNOS/NOS2 had a substantial effect. Exposure to NO donor or ascorbate revealed unutilized capacity to release HS from GPC1. In ApoE4/4-iN, nNOS/NOS1 and iNOS/NOS2 were major producers of NO. Inhibition of nNOS/NOS1 and iNOS/NOS2 in ApoE4/4-iN again showed unutilized capacity to release HS. We propose that expression of ApoE4, which retards endosome trafficking, but also activates iNOS/NOS2, results in accumulation of GPC1-SNO and slow exit of HS from endosomes which can be restored by ascorbate.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Lu Y, Vyavahare S, Gulhane M, et al (2026)

Early Hypothalamic Aromatase Loss Is Associated with Neuronal Insulin-Resistance Signaling During Progression of Experimental Alzheimer's Disease.

Biology, 15(21):.

Alzheimer's disease (AD) is increasingly recognized as a neurodegenerative disorder characterized by central insulin resistance and cerebral hypometabolism. The steroid hormone, 17β-estradiol (E2), interacts closely with insulin signaling pathways and is locally synthesized in the brain by the enzyme aromatase. However, the spatial and temporal dynamics of brain aromatase during AD progression and its relationship to central insulin resistance remain poorly understood. Using the 5xFAD mouse model, we examined whole-brain, regional, and neuron/astrocyte-specific alterations in aromatase expression along disease progression. Whole-brain aromatase expression remained unchanged at 2 months of age but progressively declined at 5 and 9 months, inversely correlating with amyloid-β plaque burden. Regional analysis of the cortex, hippocampal CA1, and hypothalamus revealed progressive aromatase loss in all regions; notably, the hypothalamus exhibited a significant decline at the earliest disease stage examined, preceding comparable changes in the cortex and hippocampus, while an age-related decline cannot be fully excluded, as only a single-aged wild-type (WT) control was used. Cell-level analysis revealed a progressive reduction in neuronal aromatase expression, whereas astrocytic aromatase displayed a biphasic response, increasing during early disease stages before declining at later stages. In parallel, neuronal insulin-resistance signaling increased progressively with disease advancement and was negatively correlated with neuronal aromatase expression across all regions examined (r = -0.82 to -0.87). Collectively, these findings demonstrate progressive regional and neuron/astrocyte-specific alterations in brain aromatase during the progression of amyloid pathology, identifying early hypothalamic vulnerability as a feature of AD-associated altered insulin signaling.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Lipski A, Koszela K, Pingot J, et al (2026)

The Impact of Selected Physical Factors on Neurogenesis-What Do We Know?.

Cells, 15(21):.

New discoveries are constantly being made regarding cognitive processes, pain perception, the development of degenerative diseases, brain aging, and many other functions of the nervous system. Neurogenesis plays a significant role in all of these processes. As a manifestation of brain plasticity, neurogenesis continues throughout life, and its intensity can vary depending on internal and external factors. The process by which neurons are generated can be disrupted. This depends, among other things, on age and represents one of the potential targets for interventions aimed at improving cognitive function. Inhibition of neurogenesis increases the risk of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other conditions that lead to dependence on others in their advanced stages. The status of the neurogenesis process can be monitored by measuring the levels of mediators in the blood. The state of the brain can be influenced by providing stimuli that increase the concentration of mediators stimulating neurogenesis. People are exposed to physical factors that can inhibit the neurogenesis process, but there are also phenomena that stimulate it. Magnetic stimulation, ultrasound, electrostimulation, light therapy, normobaric and hyperbaric oxygen therapy, whole-body cryotherapy, as well as touch and vibrations, can have a significant impact on neurogenesis and accelerate this process. The aim of this study is to present the impact of physical factors on the process of neurogenesis in humans and animals, which can significantly influence the course of this process. The review uses the wording originally used in the source articles.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Canal C, Aguilar K, Comes G, et al (2026)

Effects of Interleukin-6 Dysregulation in a Mouse Model of Alzheimer's Disease: Unraveling Complexity Beyond Amyloidosis.

Cells, 15(21):.

Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in neuroinflammation and Alzheimer's disease (AD) pathophysiology, but its contribution to the phenotype associated with amyloid precursor protein (APP) overexpression remains unclear. Here, we investigated the effects of systemic IL-6 deficiency in Tg2576 mice by assessing survival, physiological parameters, behavior, learning and memory, APP/amyloid-β (Aβ)-related pathology, and gliosis in young and aged male and female mice. In this specific cohort of animals, Tg2576 mice exhibited reduced survival and body weight, together with age- and sex-dependent alterations in behavioral and cognitive parameters. Notably, despite increased circulating Aβ40 and Aβ42, Aβ40 and Aβ42 were undetectable in the brain, and amyloid plaques were absent in Tg2576 mice compared with plaque-positive control mice. IL-6 deficiency partially rescued several of these phenotypes, particularly in females. Thus, the APP overexpression-associated phenotype observed here occurred in the absence of detectable cerebral amyloidosis, highlighting that APP overexpression-associated alterations can manifest independently of amyloid plaque deposition. Together, our findings underscore the complexity of AD pathogenesis and emphasize the multifaceted nature of IL-6 in both physiological and neurodegenerative processes, particularly in the context of AD.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Sabbir MG, K Hsiao (2026)

MT-CO2 Dysregulation in Alzheimer's Disease and Its Modulation by Photobiomodulation: Implications for Mitochondrial Function.

Cells, 15(21):.

Mitochondrial dysfunction contributes to Alzheimer's disease (AD), but the roles of individual respiratory-chain proteins remain incompletely understood. We examined mitochondrially encoded cytochrome c oxidase subunit II (MT-CO2) and nuclear encoded succinate dehydrogenase complex iron-sulfur subunit B (SDHB) in postmortem temporal cortex from cognitively normal (CN) individuals and patients with AD, Lewy body dementia/Parkinson's disease (LBD/PD), or progressive supranuclear palsy (PSP). MT-CO2 abundance was lower in AD than in CN and LBD/PD, whereas SDHB was lower in AD than in CN, LBD/PD, and PSP. A significant protein × diagnosis interaction indicated distinct diagnostic-group patterns for MT-CO2 and SDHB. In BE(2)-C neuroblastoma cells, repeated 650 nm red-light and 808 nm near-infrared (NIR) photobiomodulation increased MT-CO2 abundance, with the largest responses following 10- and 15-min exposures. shRNA-mediated MT-CO2 reduction impaired Complex IV-dependent respiration and attenuated the bioenergetic response to 808 nm treatment. Photobiomodulation did not significantly alter mitochondrially encoded MT-CO1 or MT-CO3 abundance. These findings identify alterations in MT-CO2 and SDHB in AD temporal cortex and demonstrate that MT-CO2 contributes to Complex IV-dependent respiration and photobiomodulation-associated bioenergetic enhancement. Because mitochondrial content was not independently measured, the tissue findings cannot distinguish broader mitochondrial loss from protein-specific dysregulation.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Taguchi T, P Maher (2026)

Methylglyoxal Impairs Mitochondrial Bioenergetics and Microglial Functions.

Cells, 15(21):.

Aging is accompanied by a progressive disruption of brain homeostasis, yet the molecular mechanisms underlying this age-associated deterioration remain poorly understood. Microglia play a critical role in maintaining brain homeostasis by clearing cellular debris and neurotoxic protein aggregates. Here, we investigated the effects of methylglyoxal (MG), a highly reactive endogenous metabolite that accumulates with aging, on microglial functions using the murine microglial cell line BV2. We assessed the effects of MG exposure on multiple aspects of microglial biology in both control and bacterial lipopolysaccharide (LPS)-treated cells, including phagocytic activity, cellular proliferation, cytokine secretion, mitochondrial bioenergetics, mitochondrial membrane potential, and intracellular and mitochondrial reactive oxygen species. We found that MG significantly impaired mitochondrial bioenergetics, leading to reduced cellular energy production, and markedly suppressed multiple essential microglial functions, including phagocytosis. Given the high reactivity of MG with arginine, we also investigated whether arginine depletion contributes to these functional impairments. Arginine depletion recapitulated the impairment of mitochondrial bioenergetics and microglial function induced by MG, demonstrating that arginine availability is a critical determinant of microglial metabolic fitness and immune function. These findings suggest that the age-associated accumulation of MG impairs mitochondrial bioenergetics and microglial functions, thereby potentially accelerating neurodegenerative processes.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Wei L, Jiang MQ, Zhao Y, et al (2026)

Functional Deficits and Diffusion Tensor Magnetic Resonance Imaging of the Olfactory and Vision Systems in the Alzheimer's Disease Model of Aging GluN3A Knockout Mice.

Cells, 15(21):.

Sensory dysfunction, such as olfactory and visual deficits, is a notorious symptom during the progression of Alzheimer's disease (AD) and related dementia (ADRD). The causal factor/s and structural disruptions underlying the sensory dysfunction in the AD/ADRD brain are not well understood. The NMDA receptor subunit GluN3A (NR3A) negatively regulates the receptor activity to uphold cellular Ca[2+] homeostasis. In GluN3A knockout (KO) mice, animals spontaneously develop chronic neurodegenerative excitotoxicity, cognitive decline, and AD-like pathology. Using diffusion tensor imaging (DTI), we examined neuronal network destruction together with sensory dysfunction in the GluN3A KO mouse. Specific attention was given to the selective vulnerability of the olfactory and visual nuclei, white matter injury in regional connections between subcortical centers and the cortex and hippocampus. Compared to age-matched wild-type (WT) controls (male), consistent with our early reports in younger ages, 18-month-old aging/aged GluN3A KO mice (male) suffered significant olfactory, visual and social deficits, accompanied by marked Aβ42 deposition in the brain. Ex vivo MR images of the GluN3A KO and control brains were acquired on the 7T MRI system, using a four-channel mouse array RF coil. High-resolution 3D T2-weighted RARE anatomical and DTI scans were performed. The DTI analysis revealed that GluN3A KO mice developed brain atrophy, involving significant damage in the white and gray matter of the olfactory and visual systems and impaired pathways among the superior colliculus, lateral geniculate nucleus, and the hippocampus and/or the cortex. This investigation disclosed a receptor-mediated neurodegeneration that explains sensory syndromes featured in a sporadic AD mouse model.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Choo CT, Ngian ZK, CT Ong (2026)

Cross-Species and Cell-Type-Specific H3K27ac Dynamics Link Brain Aging to Alzheimer's Disease Genes.

Cells, 15(21):.

Active H3K27ac marks are dynamically remodelled during brain aging, but their cell-type-specific regulatory roles remain unclear. We integrated genome-wide H3K27ac profiles and transcriptomes from aging Drosophila heads, mouse NeuN+ forebrain neurons, and human NeuN+/NeuN- frontal cortex cells. In Drosophila, age-gained differential (Δ) H3K4me1 and H3K27ac peaks were associated with RNA processing and immune response genes, respectively, suggesting distinct regulatory programs. Despite limited biological replicates, mouse analyses revealed a strong association between promoter-associated ΔH3K27ac and synaptic gene expression in young neurons. Age-related gene-body H3K27ac loss coincided with increased expression of genes involved in GTPase signalling and vesicular transport. In humans (n = 29), NeuN- cells exhibited more age-associated ΔH3K27ac alterations than NeuN+ cells. Genes associated with age-gained peaks were enriched for gliogenesis and amyloid precursor protein metabolic processes, while age-related transcriptional changes associated positively with super-enhancer activity. Comparison with pan-tissue aging signatures revealed shared and cell-type-specific age-related ΔH3K27ac patterns in NeuN+ and NeuN- cells. Integrative analyses showed that age-gained ΔH3K27ac peaks in NeuN- cells overlapped with AD-associated ΔH3K27ac peaks, differentially expressed AD genes, and AD GWAS-linked variants, including those mapped to BIN1 and CR1. These findings highlight extensive H3K27ac remodelling in aging NeuN- cells and its convergence with AD-associated molecular alterations.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Li Y, Ji Y, Uzun C, et al (2026)

Isoflurane and Surgery Aggravate APOE4-Dependent Lipid Dysregulation, Neural Dysfunction, and Neurological Impairment in Male Mice.

Cells, 15(21):.

Perioperative exposure to the volatile anesthetic isoflurane (ISO) during surgery (OP) has been associated with cognitive and olfactory deficits and may increase the risk of Alzheimer's disease (AD). Apolipoprotein E4 (APOE4), the strongest genetic risk factor for AD, contributes to disease pathogenesis through disrupted lipid homeostasis. However, whether ISO/OP interacts with APOE genotype to influence neurological vulnerability remains unclear. Young adult, presymptomatic humanized APOE4 and APOE3 knock-in mice underwent laparotomy under 2 h of ISO anesthesia. Microglia and astrocytes were isolated from the olfactory bulb (OB) and hippocampus (HI) for lipidomic profiling. Awake in vivo OB recordings assessed neuronal excitability and network activity, while ex vivo patch-clamp recordings assessed synaptic transmission in the OB and HI. On day 7, APOE4/ISO/OP glia showed greater lipid perturbations than APOE3/ISO/OP glia. In vivo recordings revealed genotype-dependent alterations in OB excitability and network operation, while patch-clamp recordings identified altered excitatory and inhibitory synaptic transmission in the OB and HI. APOE4/ISO/OP mice exhibited persistent odor memory deficits, transient olfactory sensitivity loss, early motor impairment, and delayed cognitive dysfunction. OB RNA sequencing identified alterations in calcium transport and metabolic pathways in APOE4 male mice at 90 days following exposure. Together, these findings demonstrate APOE4-dependent vulnerability to ISO/OP, characterized by glial lipid dysregulation, neural circuit dysfunction, and neurological impairment, and support a potential mechanistic contribution of altered lipid homeostasis.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Cipriano GL, Agostinelli E, Floramo A, et al (2026)

Tuning the Brain: How Acoustic Energies Modulate Neural and Glial Phenotypes.

International journal of molecular sciences, 27(21):.

The traditional view of neuronal communication is shifting toward a mechanobiological paradigm. This review examines how mechanical energy from diverse acoustic stimuli-audible sound and whole-body or vibrotactile vibration, low-intensity pulsed ultrasound (LIPUS), low-intensity focused ultrasound (LIFU), high-intensity focused ultrasound (HIFU), and extracorporeal shockwave therapy (ESWT)-translates into biochemical signals. Evidence is stratified throughout by model system (in vitro, animal in vivo, human) and by reported exposure dose, and sensory-pathway or network-level effects of audible sound are kept distinct from direct cellular mechanotransduction. Acoustic forces are directly detected by primary mechanosensitive ion channels, such as Piezo1 and TRPV4, and experimental evidence links this mechanotransduction to neurotrophic signaling (mechanistic target of rapamycin (mTOR); p38 mitogen-activated protein kinase (MAPK); brain-derived neurotrophic factor (BDNF)) that supports neurite outgrowth and structural repair, whereas a continuous signaling axis running from the cytoskeleton through the linker of nucleoskeleton and cytoskeleton (LINC) complex to epigenetic regulation remains a mechanistic hypothesis that has not been demonstrated in any acoustically stimulated neural cell. Furthermore, glial cells act as active mechanosensors, and emerging evidence suggests that acoustic stimulation can promote microglial polarization toward neuroprotective M2 phenotypes and may support Schwann cell-mediated peripheral nerve regeneration. We discuss the emerging concept of "acoustic pharmacology," in which specific waveforms and frequencies dictate distinct therapeutic outcomes. From targeted amyloid clearance in Alzheimer's disease to the non-invasive neural circuit control offered by sonogenetics, acoustic stimulation is a tunable but still predominantly preclinical frontier in regenerative medicine and neuromodulation: of the 144 sources cited here, seven report human studies, and the only randomized, sham-controlled evidence with a clinical endpoint concerns ablative high-intensity focused ultrasound; for the non-ablative neuromodulatory, neuroprotective, and regenerative regimes that are the subject of this review, no such trial is present in this evidence base.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Fukuhara K, Mori K, Okiyama Y, et al (2026)

DOPA-Substituted KLVFFA Peptides Potently Inhibit Amyloid-β Aggregation and Mitigate Neurotoxicity.

International journal of molecular sciences, 27(21):.

Alzheimer's disease (AD) is driven primarily by the self-assembly of amyloid-β (Aβ) peptides, a process stabilized by intermolecular π-π stacking interactions involving Phe19 and Phe20 residues of adjacent Aβ molecules. To competitively disrupt these interactions, we designed novel peptide inhibitors derived from the Aβ recognition motif KLVFFA (Aβ16-21), in which phenylalanine residues were replaced with L-3,4-dihydroxyphenylalanine (DOPA), featuring a catechol moiety capable of enhanced aromatic stacking and hydrogen bonding. The DOPA-substituted peptides effectively inhibited Aβ1-42 (Aβ42) aggregation, as demonstrated via Thioflavin T fluorescence assays, circular dichroism spectroscopy, and transmission electron microscopy. These complementary analyses collectively revealed substantial suppression of β-sheet formation and fibril elongation. Notably, the anti-aggregation potency was dependent on the substitution position, with the Phe19-substituted analog (KDF) exhibiting stronger inhibitory activity than the Phe20-substituted analog (KFD). The dual-substituted analog (KDD) displayed the greatest overall anti-aggregation activity. Molecular simulations further supported the superior activity of KDF over KFD, revealing a more favorable binding free energy for KDF compared to the parent peptide. Furthermore, the DOPA peptides potently mitigated Aβ42-induced neurotoxicity in SH-SY5Y cells, with the dual-substituted analog (KDD) providing the highest level of cytoprotection. Collectively, these findings validate that targeted modulation of aromatic interactions through DOPA substitution represents a powerful molecular strategy for controlling Aβ42 self-assembly, positioning these peptides as promising therapeutic tools for the treatment of AD.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Benchohra A, Juárez-Alía C, Serrano G, et al (2026)

Blood-CSF MiRNA Signatures in Alzheimer's Disease Reveal Novel Biomarker Candidates: A Systematic Review.

International journal of molecular sciences, 27(21):.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. MicroRNAs (miRNAs) have emerged as promising regulators of AD-related pathways and potential minimally invasive biomarkers. However, existing meta-analyses have yielded inconsistent results, and whether miRNA signatures are conserved across biological fluids remains unclear. The present work aimed to systematically review studies performing miRNA discovery or multi-candidate profiling in blood and CSF during the last 15 years, in order to identify miRNAs showing significant and consistent differential expression across independent studies. By systematically comparing the direction and consistency of miRNA dysregulation across independent studies and biological sources, we identified 80 miRNAs consistently dysregulated in both blood and CSF, revealing a reproducible cross-fluid signature of AD-associated molecular alterations. Notably, miR-451a and miR-16-5p emerged among the most consistently dysregulated miRNAs across fluids. In contrast, several miRNAs displayed divergent or compartment-specific patterns, highlighting that blood and CSF may capture distinct aspects of AD-related molecular changes. Among these, miR-484, miR-3200-3p and miR-598 were identified as novel CSF candidates, while miR-20a-5p, miR-363-3p and miR-5006-3p represented novel blood-specific candidates. Furthermore, a substantial proportion of detected miRNAs was associated with extracellular vesicle/exosomal fractions, supporting their potential stability and biological relevance. Overall, our findings demonstrate that AD-associated miRNA dysregulation comprises both conserved and biofluid-specific signatures. From a clinical perspective, the current evidence primarily supports further evaluation of miRNAs as diagnostic/discriminative biomarkers rather than validated tools for early detection, disease monitoring, or prognosis. Their clinical translation remains limited by biofluid and methodological heterogeneity and requires harmonized cross-cohort and longitudinal validation.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Issilbayeva A, Kozhakhmetov S, Kushugulova A, et al (2026)

Gut Microbiome Alterations in Alzheimer's Disease: A Shotgun Metagenomic Case-Control Study.

International journal of molecular sciences, 27(21):.

The gut microbiome has been proposed as a contributor to Alzheimer's disease (AD) pathogenesis via the microbiota-gut-brain axis, but findings across cohorts are inconsistent and scarce data exist from Central Asian populations. We used shotgun metagenomic sequencing to compare the gut microbiome of AD patients and cognitively healthy controls from Kazakhstan. In a cross-sectional case-control study (35 AD, 39 Control), we profiled taxonomic and functional (HUMAnN pathway) composition, and compared alpha/beta diversity, individual taxa and pathways, and their association with clinical and demographic variables (Mann-Whitney U test, PERMANOVA/PERMDISP, OLS regression, all BH-FDR corrected, sensitivity analysis using ANCOM-BC2), with sensitivity analyses adjusting for age and BMI and applying Bonferroni correction. Within the AD group, circulating adiponectin-measured only in this group-was examined for associations with microbiome features in an exploratory analysis. Alpha diversity was lower in AD (q < 0.05). Community composition also separated by group on PERMANOVA (R[2] = 8.6%, p = 0.001), and this separation held after adjusting for age and BMI. A total of 178 taxa differed significantly between groups (BH-FDR; 37 were also Bonferroni-significant), most prominently depletion of Faecalibacterium and enrichment of Eisenbergiella and Desulfovibrio in AD; 100 pathways differed significantly (20 Bonferroni-significant). Three clinical/demographic variables (total bilirubin, atherogenic index, BMI) were associated with specific taxa or pathways. Within the AD group, adiponectin correlated negatively with the pathway assimilatory sulfate reduction IV (rho = -0.60, q = 0.015). AD in this Central Asian cohort was associated with a less diverse, compositionally distinct gut microbiome, with depletion of butyrate-producing Firmicutes and enrichment of sulfate-reducing taxa, alongside other taxa whose direction of association differed from prior reports.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Curecheriu LM, Iliescu BF, Stanciu GD, et al (2026)

A Comparative Analysis of Microglial and Astrocyte Transplantation in an Amyloid-Induced Rat for Alzheimer's Disease.

International journal of molecular sciences, 27(21):.

Alzheimer's disease (AD) is recognized as a neuroglial disorder in which dysregulated glial responses contribute to cognitive decline. We investigated whether intrahippocampal transplantation of primary glial cells modifies cognitive trajectories in an amyloid-induced rat model of AD. Sprague-Dawley rats received bilateral hippocampal injections of pre-aggregated Aβ1-42, followed by transplantation of primary astrocytes (AA) or microglia (AM). Memory was assessed using the Y-maze and novel object recognition (NOR) tests. Body weight and serum IL-6 and TNF-α were monitored for adverse effects, and GFAP, S100, Iba1 and TREM2 immunolabeling was quantified with QuPath. Mixed-effects models showed significant session and group x session effects on Y-maze spatial novelty recognition. Both treated groups improved compared with AD animals, with a stronger late effect in the AM group and a significant group × session × sex interaction. In the NOR test, both treated groups outperformed AD animals at the final session, without differences between them. GFAP (glial fibrillary acidic protein) immunoreactivity was reduced in the AM group but remained elevated in the AA group, while TREM2 increased after microglial and decreased after astrocyte transplantation. No adverse effects were detected in the monitored parameters. Intrahippocampal glial transplantation, particularly with microglia, may influence cognitive trajectories in established amyloid pathology.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Sun Y, J Xia (2026)

Research Progress of Insulin-like Growth Factor-1 in Major Neurodegenerative Diseases.

International journal of molecular sciences, 27(21):.

Major neurodegenerative diseases (NDDs) represent a large category of disorders characterized by the progressive loss of structure, function, or eventual death of neuronal cells in the brain and spinal cord. Current conventional therapeutic strategies for NDDs primarily focus on symptomatic relief. In contrast, IGF-1 is a pleiotropic protein with neurotrophic, synaptogenic, and anti-apoptotic properties, and its neuroprotective potential has been demonstrated in various preclinical models of Alzheimer's disease, Parkinson's disease, and other NDDs. However, the clinical efficacy of IGF-1-based interventions-whether for symptomatic relief or disease modification-has not been established in humans. Research on IGF-1 as a therapeutic target for NDDs remains predominantly preclinical, and its translation into effective clinical treatments requires further validation. This narrative review summarizes the mechanisms of action and therapeutic advances of IGF-1 in the progression of NDDs, encompassing the following four aspects: (1) Strategies based on signaling pathway regulation that target key pathways such as IGF-1/PI3K/Akt to reduce neuronal loss, promote synaptogenesis and structural remodeling, correct anomalous tau hyperphosphorylation, and improve amyloid-β (Aβ) clearance impairment. (2) Strategies based on restoring central sensitivity that focus on ameliorating cerebral insulin/IGF-1 resistance and utilizing agents to indirectly restore the neuroprotective function of IGF-1, thereby delaying cognitive decline. (3) Strategies based on delivery systems: in animal models, these employ viral vectors or nanomaterials to achieve targeted brain delivery of IGF-1, effectively promoting the survival of dopaminergic and motor neurons. (4) Future research directions that further elucidate the dynamic evolution of IGF-1 signaling across different disease stages and the development of stage-specific regulatory strategies. This review discusses approaches to restoring central IGF-1 signaling, ameliorating cerebral insulin resistance, and improving brain-targeted delivery, while emphasizing that their therapeutic relevance remains predominantly preclinical and requires validation in human studies.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Huang X, Shihab MHI, Bhagchandani RL, et al (2026)

An Explainable MRI-Conditioned Generative Framework for Gene-Feature Representations in Alzheimer's Disease.

International journal of molecular sciences, 27(21):.

Magnetic resonance imaging (MRI) and peripheral-blood transcriptomics capture complementary aspects of Alzheimer's disease (AD), but whether MRI can condition a meaningful molecular representation remains unclear. We developed and independently evaluated an explainable imaging-genetics conditional variational autoencoder (IG-CVAE) in Alzheimer's Disease Neuroimaging Initiative (ADNI) and AddNeuroMed (ANM) cohorts using fixed 80% train-validation and 20% independent test sets with five-fold cross-validation. IG-CVAE comprises a genetic branch encoding expression into 128-dimensional gene-feature vectors (GFV128), an imaging branch encoding MRI into 128-dimensional MRI-feature vectors (MFV128), and a conditional variational autoencoder that generates GFV128 from MFV128. Paired analyses included 289 ADNI and 98 ANM participants. Test area under the receiver operating characteristic curve (ROC-AUC) values in ADNI/ANM were 0.646/0.851 for the genetic branch, 0.942/0.752 for the imaging branch, and 0.939/0.869 for generated GFV128. Generated-observed GFV128 agreement was moderate (cosine similarity, 0.590/0.589; coefficient of determination (R[2]), 0.161/0.211). Molecular importance was cohort-specific at the gene level, with no significant pathway-level convergence, whereas MRI perturbation showed cross-cohort convergence in cerebral white matter linked to distinct disease-informative molecular features. Overall, structural MRI retained disease-relevant information sufficient to generate disease-informative molecular representations, supporting IG-CVAE as a participant-paired hypothesis-generating imaging-transcriptomic framework while providing only limited evidence of participant-specific molecular correspondence without implying raw transcriptome reconstruction. The ANM test estimates should be interpreted cautiously given the small paired independent test set (n = 20).

RevDate: 2026-11-14
CmpDate: 2026-11-14

Sahin B, Eken Y, Sahin F, et al (2026)

Genotype-Associated Molecular Phenotypes Across Brain and Gut Compartments in Male 5xFAD Mice: Shared Latent Structure and the Limits of Individual-Level Inference.

International journal of molecular sciences, 27(21):.

Whether gut and brain molecular states covary within individual animals, rather than merely co-occurring at the group level, has rarely been tested in Alzheimer's disease models. We profiled the hippocampus, cortex, cerebellum, intestine and feces of 18 male 5xFAD (5 familial AD mutations) (B6SJL background) mice and wild-type littermates at 3, 6 and 9 months by label-free proteomics, and feces additionally by shotgun metagenomics. The hippocampal proteome reproduced the amyloid-associated signature (App, Apoe, Hexb, Clu, Gfap), and protein-set analysis showed elevated microglial, lysosomal, astrocytic and endoplasmic reticulum chaperone proteins in the hippocampus and cortex, with no detectable difference in synaptic or mitochondrial sets. Fecal Shannon diversity was reduced, and the bile-acid-modifying genera Romboutsia and Turicibacter were nearly absent in all 5xFAD animals from 3 months (cage nested within genotype). Multi-omics factor analysis recovered a genotype-associated factor shared across brain and gut views (exact permutation p = 0.00125) that explained at most 6.3% of variance in any view and was preprocessing-dependent. After removal of group structure, correlation burden did not exceed a within-cell permutation null, and neither did same-animal positive controls. The 5xFAD genotype thus alters every compartment examined, and a modest latent structure links them; because the design excludes only strong or dense individual-level coupling, the null result bounds design resolution rather than showing that gut and brain are uncoupled.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Simili OAG, Carvalho GM, Simões RSD, et al (2026)

Pantethine and Neurodegeneration: A Coenzyme A-Centered Framework Linking Metabolism, Neuroinflammation, and Mitochondrial Dysfunction.

International journal of molecular sciences, 27(21):.

Neurodegenerative diseases are a growing global health burden associated with aging and characterized by progressive neuronal dysfunction, metabolic failure, mitochondrial impairment, oxidative stress, and chronic neuroinflammation. Among the metabolic pathways implicated in these disorders, coenzyme A (CoA)-linked biology has emerged as a potentially important but still underexplored contributor to neuronal resilience and vulnerability. Pantethine, a disulfide derivative of pantetheine and a CoA-related metabolic precursor, has attracted attention because of its reported effects on cellular metabolism, redox balance, and inflammatory signaling. However, its relevance across neurodegenerative diseases remains unevenly defined, with direct support strongest in pantothenate kinase-associated neurodegeneration (PKAN) and more limited evidence in common disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). This narrative review critically examines the mechanistic and translational evidence linking pantethine to neurodegeneration. PKAN represents the most logical disease context for pantethine investigation because impaired CoA biosynthesis is proximal to disease pathogenesis, although pantethine remains investigational and its clinical efficacy has not been established. By contrast, proposed applications in AD and PD remain highly theoretical and hypothesis-generating. Nevertheless, research on pantethine and related CoA-restoring strategies may identify new intervention targets across neurodegenerative diseases and other disorders characterized by impaired cellular bioenergetics, including selected neuropsychiatric disorders. These possibilities require biomarker-informed, disease-specific studies that establish active-species exposure, target engagement, and clinically meaningful effects.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Kordas B, JK Juranek (2026)

Dietary Responses in the Diabetic Brain: Transcriptomic Convergence and Comparison with an Alzheimer's Disease Model.

International journal of molecular sciences, 27(21):.

Dietary interventions alter brain gene expression in diabetes, but the extent to which their responses agree across experiments and reduce differences from controls remains unclear. Five public transcriptomic datasets were reanalyzed, spanning human cortical fractions, rat brain regions, diabetic mouse hippocampus with intermittent fasting (IF), diabetic whole brain with ketogenic diet, and APP/PS1 and wild-type hippocampus with IF. Gene and pathway comparisons assessed agreement across experiments. Statistical tests distinguished opposing disease and dietary effects from reductions in the remaining distance from controls. IF and ketogenic diet identified 6569 and 999 genes, respectively, in diabetic mice. Their effects showed modest agreement (Pearson r = 0.205), with 447 genes significant in both experiments, including 359 with matching directions. They shared 59 pathways with a matching direction at a fixed intergene correlation of 0.01; these overlaps were not supported when correlations were estimated from the data. IF responses in diabetic and APP/PS1 hippocampus agreed poorly (r = -0.056). No human genes met a per-contrast false discovery rate < 0.05. Thirteen diabetic genes showed significant opposition of disease and IF effects; neither primary fasting experiment demonstrated contraction toward controls. The results support limited agreement between the diabetic dietary experiments and little agreement in IF responses across the examined disease contexts. They do not establish transcriptomic restoration.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Miziak B, Pluta R, SJ Czuczwar (2026)

Current Possible Newer Pharmacological Treatment Options for Alzheimer's Disease.

International journal of molecular sciences, 27(21):.

Alzheimer's disease (AD), as a chronic neurodegenerative disorder, leads to progressive dementia. About 60-80% of dementia cases are due to AD, and their incidence increases especially after the age of 65. AD is characterized by impaired memory, abnormal behavior, and impaired thinking process, which causes limitation of daily activities and a gradual loss of independence. The costs of all dementia cases are likely to reach $2 trillion in 2030 alone. Currently available pharmacological treatment of AD is, for the most part, not causal, and does not modify the course of the disease. The data search for procognitive drugs was carried out using the PUBMED and Clinical Science databases. Among the drugs with animal data and preliminary clinical trials, the following can be distinguished: fosgonimeton, blarcamesine, bezisterim, posiphen (buntanetap) and ACD856. As a rule, promising preclinical results were not confirmed in clinical trials. Some clinical expectations may be associated with posiphen and ACD856. Based on preclinical data, the following drugs seem promising: tenuigenin, JQ1, gemfibrozil, coumarin derivatives, ponicidin, salicin, calcaratarin D, new 1,3,5-triazines or 2-aminopyrymidine carboxamide derivatives, epimedium brevicornu flavonoids, and drugs affecting the glymphatic system. In general, the above-mentioned drugs counteract the pathologies leading to the occurrence of AD.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Gopalakrishna PK, Vishnumukkala T, Hein ZM, et al (2026)

Mitochondrial Dysfunction in Neurodegenerative Diseases: Molecular Mechanisms, Primary Drivers Versus Early Amplifiers, and Emerging Mitochondria-Targeted Therapeutic Strategies.

International journal of molecular sciences, 27(21):.

Mitochondria are critical for bioenergetics, calcium and redox homeostasis, and apoptosis in neurons. Neurons are especially susceptible to mitochondrial malfunction since they are terminally differentiated and have extraordinary energy requirements. Mechanisms such as defective oxidative phosphorylation, altered fission-fusion dynamics, defective mitophagy, impaired axonal transport and excessive reactive oxygen species (ROS) generation are increasingly appreciated as important mechanisms in major neurodegenerative diseases (NDDs) like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). The review discusses the structure and function of mitochondria with emphasis on oxidative phosphorylation, ROS and reactive nitrogen species (RNS) signalling, calcium-mediated excitotoxicity, lipid metabolism, and apoptotic and non-apoptotic cell-death mechanisms including necroptosis, ferroptosis, pyroptosis and parthanatos. In particular, disease-specific processes are highlighted, such as impaired mitophagy by amyloid β/tau in AD, PTEN-induced kinase 1 (PINK1)/Parkin dysfunction and complex I inhibition in PD, Superoxide Dismutase 1 (SOD1)/C9orf72-associated mitochondrial defects in ALS, and bioenergetic dysfunction by mutant huntingtin in HD. Therapeutic approaches include mitochondria-targeted antioxidants, fusion and biogenesis enhancers, fission inhibitors, inflammasome modulators, Mitochondrial Permeability Transition Pore (mPTP) inhibitors and gene therapy. Also highlighted are recent advancements such as Ubiquitin-Specific Peptidase 30 (USP30) inhibition, intercellular mitochondrial transfer and regulatory approval of a mitochondria-targeted peptide, together with evidence supporting causality and hurdles underpinning clinical translation. Graded against human-genetic, patient-tissue and model-based evidence, mitochondrial dysfunction is best supported as a primary driver in PD and genetic ALS, and as an early amplifier of proteinopathic or mutant-huntingtin toxicity in sporadic AD and HD.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Zhou X, Wang Z, H Jiang (2026)

Single-Chain Variable Fragments Targeting Plasma Exosome Amyloid-β Peptide Subtypes for Diagnosis of Alzheimer's Disease.

International journal of molecular sciences, 27(21):.

The diagnostic value of the Aβ1-42/Aβ1-40 ratio in peripheral blood as a biomarker for Alzheimer's disease (AD) remains a subject of considerable interest. However, this ratio in plasma exosomes is still underestimated. To investigate the potential clinical performances, this study has established a chemiluminescence immunoassay (CLIA) for the specific detection of Aβ1-42 and Aβ1-40 in plasma exosomes using single-chain variable fragments (scFv). Plasma samples from 20 AD patients and 20 non-AD individuals were detected by the established scFv-based CLIA, with the traditional monoclonal antibody (mAb)-based CLIA as the reference method. The results demonstrated that the plasma exosome Aβ1-42/Aβ1-40 ratio in AD patients (0.70 ± 0.35) was significantly lower than that in the non-AD control group (1.82 ± 0.79, p < 0.001). In comparison with the mAb-based assay, the scFv-based CLIA exhibited superior analytical performance, with a lower limit of detection (1 pg/mL vs. 50 pg/mL) and higher specificity (cross-reactivity rate < 5%). When the Aβ1-42/Aβ1-40 ratio of 1.075 was set as the cutoff value, the scFv-based assay achieved a diagnostic sensitivity of 90.0%, which was numerically higher than that of the mAb-based assay (85.0%), with comparable specificity (90.0% vs. 90.0%). Generally, this study has developed a highly sensitive and specific scFv-based method for the detection of plasma exosome Aβ subtypes, which supports that the plasma exosome Aβ1-42/Aβ1-40 ratio is a potential non-invasive biomarker for differentiating clinically diagnosed AD from non-AD controls in this pilot cohort.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Korkmaz MH, Bingöl Ö, The Alzheimer's Disease Neuroimaging Initiative (2026)

FDNet: A Lightweight Feature-Dominated U-Net for Hippocampus Segmentation in Brain MRI.

Diagnostics (Basel, Switzerland), 16(21):.

Background/Objectives: Hippocampus segmentation in brain MRI is challenging because the structure is small, irregularly shaped, and poorly contrasted against surrounding tissue. Increasingly complex U-Net variants improve accuracy at computational cost. We investigated whether modifying the relative contribution of encoder features within skip connections can improve performance without additional attention or gating modules. Methods: We propose FDNet, a lightweight feature-dominated U-Net that concatenates multiple identical copies of encoder feature maps with the corresponding decoder features. Three variants (FDNetX2, FDNetX3, and FDNetX4) were evaluated on sagittal MRI slices from ADNI, the Medical Segmentation Decathlon, and IBSR using five-fold cross-validation, assessed with overlap metrics and per-slice false-positive/false-negative counts. To address potential subject-level leakage in the slice-level evaluation, a subject-grouped assessment with a fixed held-out test set was additionally conducted on ADNI, with re-implemented baselines and nnU-Net v2. Results: Under the slice-level protocol, FDNet achieved Dice coefficients of 0.9339 on ADNI, 0.9470 on Decathlon, and 0.9477 on IBSR, outperforming re-implemented U-Net, Attention U-Net, and SegNet baselines with substantially fewer parameters. Under the subject-grouped protocol, the best FDNet variant reached a held-out test Dice of 0.9050 versus 0.9019 for nnU-Net. All variants significantly outperformed the three baselines after Holm correction (adjusted p < 0.0001); their advantage over nnU-Net was not significant. Conclusions: Repeated encoder features within skip connections can provide competitive hippocampus segmentation with a relatively small parameter budget. Because all results come from curated research datasets without external or cross-dataset validation, they indicate competitive performance under the evaluated conditions rather than clinical readiness.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Rahmani AH, T Sarwar (2026)

Lipidomics in Brain Health and Neurodegenerative Diseases: Mechanisms, Biomarkers, and Therapeutic Perspectives.

Diagnostics (Basel, Switzerland), 16(21):.

Lipids constitute nearly half of the brain's dry weight and play a crucial role in maintaining the function of the central nervous system (CNS). Beyond their well-known function as structural components of cellular membranes and energy storage, lipids are now identified as dynamic bioactive mediators that regulate neuronal signaling, synaptic plasticity, membrane integrity and neuroinflammatory responses. Emerging evidence demonstrates that altered lipid homeostasis is associated with the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). In this review, we highlight key pathophysiological mechanisms, including dysregulation of lipid transport by cholesterol and apolipoprotein E4 (ApoE4), which may influence the aggregation of amyloid-β in AD. We discuss sphingolipid dysregulation and impaired glucocerebrosidase activity in modulating α-synuclein pathology in PD. Furthermore, we emphasize the importance of polyunsaturated fatty acids (PUFAs) and their oxidized forms in the regulation of oxidative stress, ferroptosis, and neuronal cell death in ALS and HD. Besides mechanistic information, this review also highlights the recent advancements in modern lipidomic technologies, such as high-resolution mass spectrometry and multi-omics integration, which have facilitated the comprehensive characterization of disease-associated lipid alterations. Emerging lipid signatures, including alterations in ceramide, cholesterol metabolism and lipid droplet biogenesis in glial cells, are being investigated as candidate biomarkers and therapeutic targets. Collectively, we outline a strategy for exploiting the brain lipidome to explore the potential for personalized disease-modifying strategies against neurodegeneration by integrating mechanistic, diagnostic and therapeutic insights.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Wang Y, Cheng J, Liu T, et al (2026)

Harnessing Nanozyme Catalytic Activities for Multi-Target Intervention in Neurodegenerative Pathology.

Nanomaterials (Basel, Switzerland), 16(21):.

The therapeutic landscape for neurodegenerative diseases (NDs), including Alzheimer's and Parkinson's disease, remains challenging due to their complex, multifactorial pathogenesis and the limited efficacy of conventional therapies that primarily offer symptomatic relief. The emergence of nanozymes, nanomaterials with intrinsic enzyme-mimicking activities, presents a promising opportunity for multi-targeted intervention. This review comprehensively explores the rational design and therapeutic mechanisms of nanozymes in combating core pathological features of NDs, such as oxidative stress, protein aggregation, and neuroinflammation. We critically assess their remarkable ability to cross the blood-brain barrier and execute synergistic functions, including reactive oxygen species scavenging, misfolded protein degradation, and modulation of microglial activation. Furthermore, we provide a detailed analysis of the application and efficacy of nanozymes across major NDs, alongside a discussion on pharmacokinetics, biosafety, and prevailing challenges. By delineating the structure-enzyme-mimicking activity relationships and cellular-level mechanisms, this review aims to establish a foundational framework for the future development of nanozyme-based neuroprotective strategies, supporting ongoing efforts toward disease-modifying interventions for NDs.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Choquet de Isla J, Riscart-López J, Sánchez-Gomar I, et al (2026)

A Scoping Review of Creatine Supplementation in Alzheimer's Disease: Evidence from Preclinical and Clinical Studies.

Nutrients, 18(21):.

Background/Objectives: Although creatine supplementation has a theoretical rationale for neuroprotection, public interest has outpaced available scientific evidence. Alzheimer's disease (AD), a major and growing global health concern, is among the neurodegenerative diseases proposed to benefit from creatine supplementation. This scoping review systematically maps the existing literature on creatine supplementation for AD to identify gaps that limit translational progress. Methods: Following JBI methodology and PRISMA-ScR guidelines, a search in five electronic databases was conducted for preclinical and clinical studies evaluating creatine interventions in AD. The methodological quality of the studies was appraised using the SYRCLE and NIH tools, respectively. Results: Nine unique studies were included. The preclinical models investigated neuron apoptosis, oxidative stress, neuroinflammation, mitochondrial function, cognitive outcomes, and pathophysiological clearance. Conversely, clinical studies were limited to a pilot trial that suggested preliminary tolerability but could not establish causality. This review identifies six limitations within the current evidence: (1) a reliance on acute or non-transgenic animal models that lack construct validity; (2) a need to address sexual dimorphism; (3) a lack of studies exploring administration routes to bypass the blood-brain barrier; (4) a complete lack of independent randomized controlled trials (RCTs), with all clinical evidence originating from a single research group; (5) an absence of research assessing creatine as a preventive strategy; and (6) a shortage of assessment regarding physical syndromes, such as frailty. Conclusions: The scientific evidence for creatine in AD remains preliminary. Future research should prioritize progressive transgenic models, evaluate noninvasive administration routes, investigate effects on frailty, assess long-term preventive efficacy, account for sex as a variable, and transition to rigorous RCTs.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Cho KH, Lee YB, Kang MJ, et al (2026)

Efficacy and Safety of Cuban Policosanol on Cognitive Function and Antioxidant Status in Adults with Subjective Memory Decline: A 12-Week Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial.

Nutrients, 18(21):.

Objectives: Early non-pharmacological interventions for people with subjective memory decline (SMD) are increasingly advocated in preventing age-related cognitive decline and potentially delaying progression to mild cognitive impairment or dementia. In this multicenter clinical trial (RAYDELP1), we evaluated the efficacy and safety of sugarcane-derived Cuban policosanol (PCO) on cognitive function, superoxide dismutase (SOD) activity, inflammatory markers, and metabolic panels in adults aged 55-85 years with subjective cognitive complaints. Methods: A 12-week, randomized, double-blinded, placebo-controlled trial was conducted at Gachon University Gil Medical Center and Seoul Veterans Hospital in adults with SMD complaints. Individuals were randomized equally into three groups: placebo, PCO 20 mg group, or PCO 40 mg group. Assessment of cognitive function was performed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 11) and the Korean Mini-Mental State Examination (K-MMSE). All measurements, including SOD activity, inflammatory markers, and metabolic parameters, were analyzed in blood samples at baseline and after 12 weeks. For an exploratory subgroup analysis, participants receiving statins and those with potential ceiling effects or greater cognitive impairment based on K-MMSE scores were excluded. The K-MMSE range of 18-26 was used as an exploratory criterion to reduce heterogeneity in baseline cognitive scores, resulting in a refined analysis population of 56 participants. Results: In the refined SMD population, SOD activity increased significantly in the PCO 40 mg group after 12 weeks (mean change, +0.16 ± 0.25 U/mL; p = 0.0109) with increasing HDL-C, whereas changes in the placebo groups were not statistically significant (+0.08 ± 0.24 U/mL, p = 0.1873) with decreasing HDL-C. HDL-C levels increased in a dose-dependent manner in both the PCO 20 mg (+0.78 ± 5.1 mg/dL) and PCO 40 mg (+2.2 ± 6.7 mg/dL) groups within and between the groups. Both PCO groups showed significant differences compared with placebo in the between-group analysis and baseline-adjusted ANCOVA (p = 0.0124 and p = 0.0142, respectively). K-MMSE place-orientation scores improved significantly from baseline within both PCO groups (20 mg: 0.94 ± 0.87, p = 0.0003; 40 mg: 0.47 ± 0.77, p = 0.0155), whereas no significant within-group change was observed in the placebo group. Similarly, ADAS-Cog 11 language scores improved significantly within both PCO groups (20 mg: -1.17 ± 1.92, p = 0.0194; 40 mg: -0.95 ± 1.58, p = 0.0176). The 20 mg PCO group also showed a significant within-group decrease in Visual CPT false-alarm errors (-3.83 ± 7.13, p = 0.0357). However, between-group comparisons and baseline-adjusted ANCOVA did not demonstrate statistically significant differences in the selected cognitive outcomes. Conclusions: In the analyzed study population, HDL-C levels increased numerically in both PCO groups in a dose-dependent manner. The PCO 40 mg group showed a significant within-group increase in serum SOD activity, while improvements in selected cognitive domains were observed within both 20 mg and 40 mg PCO groups. However, no significant differences were found in between-group or ANCOVA analyses. PCO was well tolerated, and further clinical studies are warranted to confirm these exploratory findings and clarify its potential effects on cognitive function and enhancement of HDL quantity and quality.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Dragan J, Koziorowska-Gawron E, Pietkiewicz M, et al (2026)

Therapeutic Potential of Tea and Its Compounds in the Central Nervous System Disorders.

Nutrients, 18(21):.

Due to increasing prevalence and burden of the central nervous system (CNS) disorders and challenges associated with their treatment, there is ongoing search for new therapeutic targets, frequently conducted in the area of natural products. Tea (derived from Camellia sinensis) contains a wide range of bioactive compounds (polyphenols, alkaloids and amino acids) which positively affect general health and function of many systems, including CNS. The aim of this narrative review was to present up-to-date evidence of beneficial effects of tea and its compounds on CNS functions and to outline the most promising perspectives for their utility in management of neurological conditions. Based on extensive literature search, the authors demonstrate biochemical properties of tea-derived substances, molecular mechanisms of their antioxidative, anti-inflammatory and cytoprotective activity, as well as pathways of their specific impact on CNS. The evidence is presented from experimental and clinical studies investigating effects of tea and its compounds on the prevention or amelioration of neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, Huntington's disease), multiple sclerosis, cerebrovascular disease and brain tumors. Finally, limitations and barriers to these investigations are discussed and their emerging future directions are suggested.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Potu BK, Arulkandan A, Gopalakrishna PK, et al (2026)

Anatomical and Molecular Foundations of the Gut-Brain Axis in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Translation.

Nutrients, 18(21):.

Alzheimer's disease (AD) is a complex disease that involves systemic, vascular, and metabolic components affecting the brain, in addition to amyloid-beta (Aβ) and tau pathology. The microbiota-gut-brain axis, a bidirectional communication network between the gastrointestinal tract and the central nervous system, involving neural, immune, endocrine, and metabolic pathways, has arisen as a mechanistically plausible and clinically relevant contributor to AD pathogenesis among these systemic contributors. This review integrates information from human observational research, preclinical transgenic and germ-free models, and clinical trials to assess how gut dysbiosis, intestinal barrier dysfunction, and microbial metabolites converge on amyloidogenic and tau-associated pathways. In preclinical models, disruption of intestinal barrier integrity is proposed to allow translocation of lipopolysaccharide and bacterial amyloids into the systemic circulation, activating Toll-like receptor and NLRP3 inflammasome signaling that may prime microglia and astrocytes towards a chronic neuroinflammatory state. Further, dysbiosis-mediated changes in short-chain fatty acid, tryptophan-kynurenine, and bile acid metabolism may influence amyloid precursor protein processing, microglial clearance capability, and tau phosphorylation. Preclinical germ-free and fecal-transfer investigations provide fundamental evidence for these pathways in rodent models, while human case-control and Mendelian randomization data indicate converging yet diverse associations that have not yet established underlying directionality in human disease. Therapeutic modulation of the axis has shown promising early phase and observational signals using probiotics, synbiotics, dietary pattern interventions, fecal microbiota transplantation and pharmacological targeting of the GLP-1 pathway; however, the phase 3 EVOKE and EVOKE+ trials of oral semaglutide did not meet their primary cognitive endpoint, and heterogeneity of trials, short follow-up, and inconsistent reporting of biomarkers currently preclude definitive conclusions. We conclude that the microbiota-gut-brain axis is a biologically plausible and therapeutically tractable component of AD pathophysiology, but translation from mechanistic plausibility to clinical utility will depend upon longitudinal, biomarker-anchored and adequately powered interventional trials in genetically and microbiologically diverse populations. Because diet is among the most readily modifiable determinants of gut microbiome composition and function, this review prioritizes dietary patterns, prebiotic fibers, and probiotic or synbiotic supplementation as practical strategies for investigating the microbiota-gut-brain axis in AD. Their disease-modifying efficacy remains unproven; therefore, mechanistic and pharmacological approaches are discussed as complementary avenues for informing future research.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Chamut S, Nowak H, Dadras S, et al (2026)

Mapping the Oral-Nutrition-Brain Axis in Aging: A Scoping Review of Evidence Linking Oral Health, Nutrition, and Cognitive Outcomes.

Nutrients, 18(21):.

Background: Oral health, nutrition, and neurocognitive health are increasingly recognized as components of healthy aging; however, their multidimensional relationships and plausible biological connections relevant to Alzheimer's disease and related dementia (AD/ADRD) risk remain incompletely characterized. Objective: To systematically map evidence linking oral conditions and function, nutrition-related factors and biomarkers, and neurocognitive outcomes in adults aged ≥65 years, and conceptualize an integrative Oral-Nutrition-Brain Axis (ONBA). Methods: This scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR guidance. Five electronic databases were searched for studies published from 2010 through June 2025. Evidence was harmonized across oral and functional indicators, nutritional/metabolic/inflammatory biomarkers, and neurological and cognitive outcomes. Results: Of 3415 records identified, 1988 unique records were screened, and 120 studies met eligibility criteria. Evidence was predominantly observational and geographically concentrated in East Asia. Periodontal inflammation, compromised dentition, impaired functional occlusion and masticatory performance were consistently associated with nutritional vulnerability, poorer cognitive performance, cognitive decline, and adverse AD/ADRD outcomes. Co-occurring nutritional and systemic markers included low body weight, hypoalbuminemia, low serum vitamin B12 and folate, hyperhomocysteinemia, and elevated inflammatory biomarkers. Mapped findings aligned across three proposed conceptual frameworks: inflammatory-microbial, nutritional-metabolic, and sensorimotor deafferentation axes. Studies incorporating neuroimaging biomarkers or integrating all three ONBA domains simultaneously remained limited. Conclusions: Oral health and functional dentition may represent key modifiable proxies associated with nutritional and neurocognitive vulnerability in older adults. Longitudinal studies incorporating harmonized oral, nutritional, inflammatory, and neurological phenotypes are needed to clarify temporal sequence, evaluate potential explanatory relationships, and inform multi-domain risk assessment for healthy cognitive aging.

RevDate: 2026-11-14
CmpDate: 2026-11-14

Drăgoi CM, Nicolae AC, IB Dumitrescu (2026)

The Circadian Diet in Age-Related Neurodegeneration: Nutrient Timing, Sleep, and Mitochondrial Mechanisms.

Nutrients, 18(21):.

Circadian rhythms coordinate sleep-wake regulation, endocrine secretion, nutrient handling and cellular energy metabolism. Circadian and sleep disturbances are associated with metabolic and cardiovascular morbidity and with neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), although whether restoring circadian alignment modifies neurodegeneration remains uncertain. This narrative review examines chrononutrition within the broader context of sleep regulation, physical activity and circadian care, distinguishing evidence from cellular and animal models, observational studies and clinical trials. Meal timing and dietary composition act as signals to peripheral clocks, while NAD[+], sirtuins and AMP-activated protein kinase link nutrient availability with clock regulation and mitochondrial metabolism. We appraise time-restricted eating, protein distribution, NAD[+] precursors, tryptophan- and melatonin-containing foods, magnesium, omega-3 fatty acids, polyphenols and fermentable fiber. Experimental findings provide mechanistic plausibility, but metabolic improvements and target engagement have not translated into demonstrated neuroprotection. Clinical application must account for levodopa-protein interactions, undernutrition, frailty and sarcopenia. Adequately powered trials with circadian-phase assessment, controlled energy intake and clinically meaningful neurological outcomes are required before a "circadian diet" can be established as a disease-modifying intervention.

▼ ▼ LOAD NEXT 100 CITATIONS

RJR Experience and Expertise

Researcher

Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.

Educator

Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.

Administrator

Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.

Technologist

Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.

Publisher

While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.

Speaker

Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.

Facilitator

Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.

Designer

Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.

963 Red Tail Lane
Bellingham, WA 98226

206-300-3443

E-mail: RJR8222@gmail.com

Collection of publications by R J Robbins

Reprints and preprints of publications, slide presentations, instructional materials, and data compilations written or prepared by Robert Robbins. Most papers deal with computational biology, genome informatics, using information technology to support biomedical research, and related matters.

Research Gate page for R J Robbins

ResearchGate is a social networking site for scientists and researchers to share papers, ask and answer questions, and find collaborators. According to a study by Nature and an article in Times Higher Education , it is the largest academic social network in terms of active users.

Curriculum Vitae for R J Robbins

short personal version

Curriculum Vitae for R J Robbins

long standard version

RJR Picks from Around the Web (updated 11 MAY 2018 )